```
LE 'USPAT' ENTERED AT 07:50:33 ON 04 MAR 96
  * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
  *                W E L C O M E   T O   T H E                    *
  *          U. S.   P A T E N T   T E X T   F I L E              *
  * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
=> e cobbold/in
E1          11      COBBLEDICK, DAVID S/IN
E2           2      COBBLEDICK, DAVID STANLEY/IN
E3           0 --> COBBOLD/IN
E4           1      COBBOLD, STEPHEN P/IN
E5           1      COBBS, CARRINGTON S/IN
E6           1      COBBS, DAVID/IN
E7           3      COBBS, DAVID C/IN
E8           1      COBBS, DAVID H/IN
E9          12      COBBS, JAMES H/IN
E10          6      COBBS, KEITH E/IN
E11          1      COBBS, RICHARD W/IN
E12         17      COBBS, WALTER H JR/IN
=> s e4
L1           1 "COBBOLD, STEPHEN P"/IN
=> e waldmann, herman ?/in
E1           4      WALDMANN, HERBERT/IN
E2           1      WALDMANN, HERMAN/IN
E3           0 --> WALDMANN, HERMAN ?/IN
E4          18      WALDMANN, HERMANN/IN
E5           1      WALDMANN, HERRMANN/IN
E6           1      WALDMANN, HORST/IN
E7           1      WALDMANN, JACOBO/IN
E8           8      WALDMANN, JOHN J/IN
E9           1      WALDMANN, JOHN JOSEPH/IN
E10          2      WALDMANN, JUERGEN/IN
E11          5      WALDMANN, JURGEN/IN
E12         10      WALDMANN, KARL/IN
=> s e2
L2           1 "WALDMANN, HERMAN"/IN
=> d l1

1.  4,841,025, Jun. 20, 1989, Antibody preparations; **Stephen P.
Cobbold**, et al., 530/387.3; 424/133.1, 141.1, 154.1, 155.1; 435/240.27;
530/388.1, 388.2, 388.7, 388.75, 388.8, 412, 413, 808; 935/107, 110
[IMAGE AVAILABLE]
=> d l2

1.  4,841,025, Jun. 20, 1989, Antibody preparations; Stephen P. Cobbold,
et al., 530/387.3; 424/133.1, 141.1, 154.1, 155.1; 435/240.27; 530/388.1,
388.2, 388.7, 388.75, 388.8, 412, 413, 808; 935/107, 110 [IMAGE
AVAILABLE]
=> s cd4(p)tolerance
          845 CD4
        60438 TOLERANCE
L3         10 CD4(P)TOLERANCE
=> d l3 1-10

1.  5,480,872, Jan. 2, 1996, Method of providing enternal nutritional
support to persons infected with human immunodeficiency virus; Frederick
O. Cope, et al., 514/21; 426/641, 648, 654, 656, 657 [IMAGE AVAILABLE]

2.  5,422,274, Jun. 6, 1995, Internal deletion mutants of soluble
```

T4(CD4); Paul J. Maddon, et al., 435/320.1; 424/188.1, 208.1; 435/69.4, 69.6, 172.3; 530/388.35; 536/23.1 [IMAGE AVAILABLE]

3. 5,403,826, Apr. 4, 1995, Nutritional product for persons infected with human immunodeficiency virus; Frederick O. Cope, et al., 514/21; 426/656, 800; 514/2, 23 [IMAGE AVAILABLE]

4. 5,397,702, Mar. 14, 1995, Assay for and treatment of autoimmune diseases; Michael D. Cahalan, et al., 435/69.1, 6, 172.3; 536/23.1, 23.5, 25.5 [IMAGE AVAILABLE]

5. 5,374,620, Dec. 20, 1994, Growth-promoting composition and its use; Ross G. Clark, et al., 514/12, 4, 21; 530/399; 930/10, 120 [IMAGE AVAILABLE]

6. 5,330,972, Jul. 19, 1994, Method of impeding apoptosis of CD4 cells in persons infected with human immunodeficiency virus; Frederick O. Cope, 514/2; 426/44, 46, 419, 656, 658, 800; 514/21; 530/378 [IMAGE AVAILABLE]

7. 5,248,499, Sep. 28, 1993, Control of microbial infections in transplant patients; Christine Czarniecki, et al., 424/85.2, 85.1, 85.5 [IMAGE AVAILABLE]

8. 5,126,433, Jun. 30, 1992, Soluble forms of the T cell surface protein CD4; Paul J. Maddon, et al., 530/395, 350, 380, 387.2, 387.9, 389.1 [IMAGE AVAILABLE]

9. 5,110,906, May 5, 1992, Derivatives of soluble T-4; Paul J. Maddon, et al., 530/350; 435/5, 974; 530/395, 821; 930/221 [IMAGE AVAILABLE]

10. 5,081,226, Jan. 14, 1992, Synthetic peptides sharing sequence homology with the HIV envelope protein; Jay A. Berzofsky, et al., 530/324; 424/188.1, 208.1; 514/2, 8, 10, 12, 13, 14, 21; 530/325, 326, 327, 350 [IMAGE AVAILABLE]

=> d l3 4,8,9 kwic

US PAT NO: 5,397,702 [IMAGE AVAILABLE] L3: 4 of 10

DETDESC:

DETD(104)

Augmented type 1 K.sup.+ channel expression appears to be a valuable marker for **CD4**.sup.- CD8.sup.- cells associated with murine SLE, type-1 diabetes mellitus and chronic EAE. These results focus attention on the possible role of **CD4**.sup.- CD8.sup.- T cells in the pathogenesis of autoimmune diseases and emphasize the potential value of combining electrophysiological approaches with immunological. . . molecular techniques in the study of autoimmunity. Our results provide for exploiting the abundance of type 1 K.sup.+ channels in **CD4**.sup.- CD8.sup.- T cells in testing the disease process. Investigation of the effects of type 1 K.sup.+ channel-specific drugs on the development of autoimmunity is made possible by this invention. Recent reports show that gamma/delta **CD4**.sup.- CD8.sup.- T cells respond to mycobacterial antigens and accumulate in leprosy skin lesions, cutaneous leishmaniasis, and rheumatoid arthritic joints (Modlin,. . . et al., Nature 339, 544 (1989); Holishitz, et al., Nature 339, 226 (1989)). By inducing the aggregation of monocytes, these **CD4**.sup.- CD8.sup.- T cells may

contribute to inflammatory processes (Modlin, et al., Nature 339, 544 (1989)). Alpha/beta TCR.sup.+ **CD4**.sup.- CD8.sup.- T cells have been reported to act as helper cells, inducing autoreactive B cells to secrete pathogenic anti-DNA antibodies (Datta, et al., J. Exp. Med. 165, 1252 (1987); Sainis and Datta, J. Immun. 140, 2215 (1988)). **CD4**.sup.- CD8.sup.- T cells have also been reported to abrogate oral **tolerance** (Kitamura, et al., J. Immunol. 139, 3251 (1987)). Collectively, these observations show that **CD4**.sup.- CD8.sup.- T cells apparently have a significant role in biologically relevant immune responses and apparently are involved in the mechanisms. . . . triggered by mitogens or antigens (e.g., E. coli or CFA), may induce abundant expression of type l K.sup.+ channels on **CD4**.sup.- CD8.sup.- T cells, regardless of the type of TCR they display on their cell surface.

US PAT NO: 5,126,433 [IMAGE AVAILABLE] L3: 8 of 10

DETDESC:

DETD(17)

The . . . this invention also has utility as an inhibitor of T4.sup.+ cell function Numerous studies suggest a critical role for the **CD4** receptor (**CD4** is general terminology for the human T4 receptor and its counterparts in other mammalian cells) in immune **tolerance**, particularly in the pathogenesis and progression of autoimmune diseases and in host specific graft rejection. Of particular relevance to sT4 are the observations with anti-**CD4** Mabs. Through their association with the **CD4** receptor, certain of these Mabs ameliorate autoimmune responses and graft rejection. Examples of such action include inhibition of T-cell function in vitro, for example, antigen induced proliferation, lymphokine secretion and helper cell function by certain anti-**CD4** Mabs; treatment of systemic lupus erythematosus by administration of anti-**CD4** Mabs to retard the onset of murine lupus; and grafting studies in mice wherein a single dose of murine Mab directed against the murine **CD4** receptor results in acceptance of the allograft.

US PAT NO: 5,110,906 [IMAGE AVAILABLE] L3: 9 of 10

DETDESC:

DETD(10)

The . . . this invention also has utility as an inhibitor of T4.sup.+ cell function. Numerous studies suggest a critical role for the **CD4** receptor (**CD4** is general terminology for the human T4 receptor and its counterparts in other mammalian cells) in immune **tolerance**, particularly in the pathogenesis and progression of autoimmune diseases and in host specific graft rejection. Of particular relevance to sT4 are the observations with anti-**CD4** Mabs. Through their association with the **CD4** receptor, certain of these Mabs ameliorate autoimmune responses and graft rejection. Examples of such action include inhibition of T-cell function in vitro, for example, antigen induced proliferation, lymphokine secretion and helper cell function by certain anti-**CD4** Mabs; treatment of systemic lupus erythematosus by administration of anti-**CD4** Mabs to retard the onset of murine lupus; and grafting studies in mice wherein a single dose of murine Mab directed against the murine **CD4** receptor results in acceptance of the allograft.
=> d l3 4,8,9 fro

US PAT NO: 5,397,702 [IMAGE AVAILABLE] L3: 4 of 10
DATE ISSUED: Mar. 14, 1995
TITLE: Assay for and treatment of autoimmune diseases
INVENTOR: Michael D. Cahalan, Laguna Beach, CA
Kanianthara G. Chandy, Laguna Beach, CA
Stephan Grissmer, Irvine, CA
Sanjiu Ghanshani, Chino Hills, CA
George A. Gutman, Costa Mesa, CA
Brent A. Dethlefs, Fountain Valley, CA
ASSIGNEE: The Regents of the University of California, Oakland, CA (U.S. corp.)
APPL-NO: 07/955,916
DATE FILED: Oct. 2, 1992
REL-US-DATA: Continuation-in-part of Ser. No. 668,609, Mar. 13, 1991, abandoned, which is a continuation-in-part of Ser. No. 319,499, Mar. 6, 1989, abandoned.
FRN-PRIOR: World Intellectual Property Organization
PCT/US90/01197 Mar. 5, 1990
INT-CL: [6] C12P 21/06
US-CL-ISSUED: 435/69.1, 172.3, 6; 536/23.1, 23.5, 25.5
US-CL-CURRENT: 435/69.1, 6, 172.3; 536/23.1, 23.5, 25.5
SEARCH-FLD: 536/23.1, 23.5, 25.3; 530/350, 839; 424/570; 435/69.1, 172.3, 6; 436/149, 506, 501, 811, 815
REF-CITED:

FOREIGN PATENT DOCUMENTS

8906967	8/1989	World Intellectual Property Organization
8906968	8/1989	World Intellectual Property Organization

OTHER PUBLICATIONS

Till, et al., Biological Abstracts, vol. 87, No. 4, p. AB-167 (1989).
Katz, et al., Biological Abstracts, vol. 85, No. 7, p. AB-651 (1988).
Tempel, et al., Nature 332, 837 (1988).
Baumann, et al., The EMBO Journal 7, 2457 (1988).
McKinnon, The Journal of Biological Chemistry 264, 8230 (1989).
Frech, et al., Nature 642, 340 (1989).
Miller, Trends Neurosci. 13, No. 6, 197 (1990).
Cook TIPS, 9 Elsevier Publications 21-28 (1988).
Robertson, et al., Jour. Medicinal Chem. 33 No. 6, 1529 (1990).
Swanson, et al., Neuron 4, 929 (1990).
Chandy, et al., European J. Immunol. 20, 747 (1990).
Ghanshani, et al., Abstract submitted for the Biophysics Conference in Vancouver, July 29 to Aug. 3, 1990.
Gupta, et al., Cell Immunol. 104 (2), 290 (1987) Abstract.
Chandy, et al., Science 247, 973 (1990).
Chandy, et al., Abstract Biophysical Meeting, Baltimore, Md., Feb. (1990).
Grissmer, et al., Abstract, Tenth International Biophysical Congress, Vancouver, Canada 29 July to 3 Aug. 1990.
Douglass, et al., J. Immunol. 144, 4841 (1990).
Stuhmer, et al., EMBOJ 8, 3235 (1989).
Swanson, et al., Biophysical Journal 57, 211a (1990).
McCormack, et al., Proc. Natl. Acad. Sci. USA 87, 5227 (1990).
Ribera, Neuron 5, 691 (1990).
Chandy, et al., Biophysical Journal 61, Abstract #1484 (1992).

Grissmer, et al., Proc. Natl. Acad. Sci. USA 87, 9411 (1990).
Douglass, et al., The Journal of Immunology 144, 4841 (1990).
Luneau, et al., Pro. Natl. Acad. Sci. USA 88, 3932 (1991).
Murakami, et al., FASEB Journal 4, Abstract #2404 (1990).
Chandy, et al., American Rheumatism Association, 53rd Annual Scientific Meeting, Ohio, (1989).
Chandy, et al., Society for Neuroscience Abstracts 15, #220.1, (1989).
Grissmer, et al., J. Immunol. 145, 2105 (1990).
Mathew, et al., Society for Neuroscience Abstracts 15, Abstract #230.12 (1989).
Ramaswami, et al., Mol. Cell. Neurosciences, 1, 214 (1990).
Yokoyama, et al., FEBS Letters 259, 37 (1989).
Grupe, et al., The EMBO Journal 9, (1990).
Theofilopoulous, et al., Adv. Immunol. 37, 269 (1985).
Shapiro, et al., Biophys. J. 53, 550a (1988).
Lewis, et al., Science 239, 771 (1988).
DeCoursey, et al., J. Gen. Physiol. 89, 405 (1987).
Chandy, et al., Science 233, 1197 (1986).
Grissmer, et al., J. Immunology 141, 1137 (1988).
DeCoursey, et al., Nature 307, 465 (1984).
Wofsy and Seaman, J. Exp. Med. 161, 378 (1985).
Wofsy, et al., J. Immunol. 134, 852 (1985).
Santoro, et al., J. Exp. Med. 167, 1713 (1988).
Waldor, et al., Science 227, 415 (1985).
Ranges, et al., J. Exp. Med. 162, 1105 (1985).
Christadoss and Dauphinee, J. Immunol. 136, 2437 (1986).
Wofsy, J. Immunol. 136, 4554 (1986).
Sainis and Datta, J. Immunol. 140, 2215 (1988).
Shivakumar, et al., FASEB J. 3, A492 (No. 1548) (Feb., 1989).
Datta, J. Exp. Med. 165, 1252 (1987).
DeCoursey, et al., Nature 307, 465 (1984).
Miller, et al., J. Immunol. 140, 52 (1988).
Koike, et al., Diabetes 36, 539 (1987).
Yokoyama et al, FEBS Letters, vol. 259, No. 1, 37-42, Dec. 1989, "Potassium Channels from NG 108-15 Neuroblastoma-Glioma Hybrid Cells".
Ohara et al, Proc. Natl. Acad. Sci USA, vol. 86 pp. 5673-5677, Aug. 1989, "One-Sided Polymerase Chain Reaction: The Amplification of CDNA".
Luneau et al, Proc. Natl. Acad. Sci USA, vol. 88, pp. 3932-3936, May 1991, "Alternative Splicing Contributes to K.sup.+ Channel Diversity in the Mammalian Central Nervous System".
Rettig et al, The EMBO Journal, vol. 11, No. 7, pp. 2473-2486, 1992.
ART-UNIT: 183
PRIM-EXMR: Christine M. Nucker
ASST-EXMR: Laurie Scheiner
LEGAL-REP: Walter H. Dreger

ABSTRACT:
This disclosure relates to the general diagnosis and treatment of autoimmune diseases with materials identified in assays based upon the finding herein that such diseases manifest by elevated numbers of type 1 K.sup.+ channels in abnormal CD4.sup.- CD8.sup.- T cells.
5 Claims, 40 Drawing Figures

US PAT NO: 5,126,433 [IMAGE AVAILABLE] L3: 8 of 10
DATE ISSUED: Jun. 30, 1992
TITLE: Soluble forms of the T cell surface protein CD4
INVENTOR: Paul J. Maddon, New York, NY

Leonard Chess, Scarsdale, NY
Richard Axel, New York, NY
Robin Weiss, London, England
Dan R. Littman, San Francisco, CA
J. Steven McDougal, Atlanta, GA
ASSIGNEE: The Trustees of Columbia University in the City of New York, New York, NY (U.S. corp.)
APPL-NO: 07/114,244
DATE FILED: Oct. 23, 1987
REL-US-DATA: Continuation-in-part of Ser. No. 898,587, Aug. 21, 1986, abandoned.
INT-CL: [5] C07K 3/00; A61K 35/14
US-CL-ISSUED: 530/395, 350, 380, 387.2, 389.1, 387.9
US-CL-CURRENT: 530/395, 350, 380, 387.2, 387.9, 389.1
SEARCH-FLD: 435/6; 536/27; 530/395, 386, 387
REF-CITED:

U.S. PATENT DOCUMENTS

4,520,113	5/1985	Gallo et al.
4,621,054	11/1986	Suzuki et al.
4,629,783	12/1986	Cosand
4,663,436	5/1987	Elder et al.
4,761,371	8/1988	Bell et al.
4,816,567	3/1989	Cabilly et al.

OTHER PUBLICATIONS

Littman et al. Cell V40 pp. 237-246 (1985).
Maire et al. Molecular and Cellular Biology 6(4) pp. 1315-1319.
Littman, D. R. et al., Chemical Absracts, vol. 103, p. 175, column 1, abstract No. 190738 (1985).
Littman, D. R. et al., ICSU Short Rep., vol. 2, (Adv. Gene Tech.), pp. 233-234 (1985).
Maddon, P. J., et al., Cell vol. 42, pp. 93-104 (1985).
Maddon, P. J. et al., Cell, vol. 47, pp. 333-348 (1986).
McDougal, J. S. et al., J. of Immunology, pp. 2937-2944 (1986).
Isobe, M. et al., Proc Natl. Acad. Sci USA, vol. 83, pp. 4399-4402 (1986).
McDougal, J. S. et al., Science, vol. 231, pp. 382-385 (1986).
Blue, M. et al., J. of Immunology, vol. 134, pp. 2281-2286 (1985).
Dalgleish, A. G. et al., Nature, vol. 312, pp. 763-767 (1984).
Ratner, L. et al., Nature, vol. 313, pp. 277-284 (1985).
Wong-Staal, F. et al., Nature, vol. 317, pp. 395-403 (1985).
Klatzmann, D. et al., Nature, vol. 312, pp. 767-768 (1984).
Terhorst, C. et al., Science, vol. 209, pp. 520-521 (1980).
Rose, J. K. & Bergmann, J. E., Cell, vol. 30, pp. 753-762 (1982).
Wills, J. W. et al., J.Cell Bio., vol. 99, pp. 2011-2023 (1984).
Springer, T. A. & Strominger, J. L., P.N.A.S., U.S.A., vol. 73 (7), pp. 2481-2485 (1976).
ART-UNIT: 187
PRIM-EXMR: Margaret Moskowitz
ASST-EXMR: Scott A. Chambers
LEGAL-REP: John P. White

ABSTRACT:
A single-stranded nucleic acid molecule which encodes an amino acid sequence comprising at least a portion of a T4 glycoprotein is provided. Additionally, amino acid sequences which comprise at least a portion of a T4 glycoprotein and are useful as a prophylaxis for treating a subject with acquired immune deficiency syndrome are provided. These amino acid

sequences, are capable of specifically forming a complex with a human immunodeficiency virus envelope glycoprotein and which are soluble in an aqueous solution. Monoclonal antibodies directed to the water-soluble amino acid sequences of the present invention may be used as vaccines for immunizing a subject against acquired immune deficiency syndrome.

2 Claims, 18 Drawing Figures

US PAT NO: 5,110,906 [IMAGE AVAILABLE] L3: 9 of 10
DATE ISSUED: May 5, 1992
TITLE: Derivatives of soluble T-4
INVENTOR: Paul J. Maddon, New York, NY
Richard Axel, New York, NY
Raymond W. Sweet, Bala Cynwyd, PA
James Arthos, Ann Arbor, MI
ASSIGNEE: The Trustees of Columbia University in the City of New York, New York, NY (U.S. corp.)
Smithkline Beckman Corporation, Philadelphia, PA (U.S. corp.)
APPL-NO: 07/160,348
DATE FILED: Feb. 24, 1988
REL-US-DATA: Continuation-in-part of Ser. No. 114,244, Oct. 23, 1987, which is a continuation-in-part of Ser. No. 898,587, Aug. 21, 1986, abandoned.
INT-CL: [5] C07K 13/00
US-CL-ISSUED: 530/350; 435/5, 974; 530/395, 829; 930/221
US-CL-CURRENT: 530/350; 435/5, 974; 530/395, 821; 930/221
SEARCH-FLD: 530/387, 395, 350, 829; 930/221; 435/5, 974
REF-CITED:

U.S. PATENT DOCUMENTS

4,520,113	5/1985	Gallo et al.	435/5
4,621,054	11/1986	Suzuki et al.	435/69
4,629,783	12/1986	Cosand	435/5
4,663,436	5/1987	Elder et al.	530/324

FOREIGN PATENT DOCUMENTS

8801304	2/1988	World Intellectual Property Organization

OTHER PUBLICATIONS

Littman, D. R. et al., Chemical Abstracts, vol. 103, p. 175, col. 1, Abstract No. 190738 (1985).
Littman, D. R. et al., ICSU Short Rep., vol. 2, (Adv. Gene Tech.), pp. 233-234 (1985).
Maddon, P. J. et al., Cell, vol. 42, pp. 93-104 (1985).
Terhorst, C. et al., Science, vol. 209, pp. 520-521 (1980).
Maddon, P. J. et al., Cell, vol. 47, pp. 333-348 (1986).
McDougal, J. S. et al., J. of Immunology, pp. 2937-2944 (1986).
Isobe, M. et al., Proc. Natl. Acad. Sci. U.S.A., vol. 83, pp. 4399-4402 (1986).
Ratner, L. et al., Nature, vol. 313, pp. 277-284 (1985).
Wong-Staal, F. et al., Nature, vol. 317, pp. 395-403 (1985).
Klatzmann, D. et al., Nature, vol. 312, pp. 767-768 (1984).

ART-UNIT: 187
PRIM-EXMR: Christine Nucker
LEGAL-REP: John P. White, Antoinette F. Konski

ABSTRACT:
This invention provides a therapeutic agent capable of specifically

forming a complex with human immunodeficiency virus envelope glycoprotein which comprises a polypeptide. In one embodiment of the invention, the amino acid sequence of the polypeptide comprises the amino acid sequence shown in FIG. 6 from about +1 to about +185 fused to the amino acid sequence from about +353 to about +371. In another embodiment of the invention, the amino acid sequence of the polypeptide comprises the amino acid sequence shown in FIG. 6 from about +1 to about +106 fused to the amino acid sequence from about +353 to about +371. In yet a further embodiment of the invention, the amino acid sequence of the polypeptide comprises the amino acid sequence shown in FIG. 6 from about +1 to about +185.

This invention also provides a method for treating a subject infected with a human immunodeficiency virus. The method comprises administering to the subject an effective amount of a pharmaceutical composition comprising an effective amount of a therapeutic agent of the invention and a pharmaceutically acceptable carrier.

3 Claims, 44 Drawing Figures

```
=> s cd4 and (non(w)deplet? or nondeplet?)
           845 CD4
        709585 NON
         40946 DEPLET?
           148 NON(W)DEPLET?
            45 NONDEPLET?
L4           0 CD4 AND (NON(W)DEPLET? OR NONDEPLET?)
=> s (nondeplet? or non(w)deplet?) and antibod?
            45 NONDEPLET?
        709585 NON
         40946 DEPLET?
           148 NON(W)DEPLET?
         18940 ANTIBOD?
L5           5 (NONDEPLET? OR NON(W)DEPLET?) AND ANTIBOD?
=> d l5 1-5

1.  5,229,275, Jul. 20, 1993, In-vitro method for producing
antigen-specific human monoclonal **antibodies**; Diana K. Goroff,
435/70.1; 424/85.2; 435/70.21, 70.4, 240.2, 240.27; 530/351, 387.1, 388.1
[IMAGE AVAILABLE]

2.  5,169,937, Dec. 8, 1992, Method for producing stable glycosylated
hemoglobin; Richard Smith, et al., 530/385; 436/67; 514/6 [IMAGE
AVAILABLE]

3.  4,971,801, Nov. 20, 1990, Biologic response modifier; Richard W.
Urban, 424/450; 264/4.3; 424/85.2, 282.1; 428/402.2; 436/829; 514/885
[IMAGE AVAILABLE]

4.  4,876,188, Oct. 24, 1989, Novel immunochemical method for assaying
stable glycosylated hemoglobin; Richard Smith, et al., 435/7.25, 7.92,
28; 436/67, 512, 518, 536, 543, 548, 808, 811, 815, 825 [IMAGE AVAILABLE]

5.  4,322,680, Mar. 30, 1982, Chemically sensitive JFET transducer
devices utilizing a blocking interface; Jiri Janata, et al., 324/71.2
[IMAGE AVAILABLE]
=> d l5 1-5

1.  5,229,275, Jul. 20, 1993, In-vitro method for producing
antigen-specific human monoclonal **antibodies**; Diana K. Goroff,
435/70.1; 424/85.2; 435/70.21, 70.4, 240.2, 240.27; 530/351, 387.1, 388.1
```

[IMAGE AVAILABLE]

2. 5,169,937, Dec. 8, 1992, Method for producing stable glycosylated hemoglobin; Richard Smith, et al., 530/385; 436/67; 514/6 [IMAGE AVAILABLE]

3. 4,971,801, Nov. 20, 1990, Biologic response modifier; Richard W. Urban, 424/450; 264/4.3; 424/85.2, 282.1; 428/402.2; 436/829; 514/885 [IMAGE AVAILABLE]

4. 4,876,188, Oct. 24, 1989, Novel immunochemical method for assaying stable glycosylated hemoglobin; Richard Smith, et al., 435/7.25, 7.92, 28; 436/67, 512, 518, 536, 543, 548, 808, 811, 815, 825 [IMAGE AVAILABLE]

5. 4,322,680, Mar. 30, 1982, Chemically sensitive JFET transducer devices utilizing a blocking interface; Jiri Janata, et al., 324/71.2 [IMAGE AVAILABLE]
=>

```
begin 55,72,154,399,351

      30aug97 14:17:27 User208760 Session D877.2
           $0.00    0.004 Hrs File410
    $0.00  Estimated cost File410
    $0.00  Estimated cost this search
    $0.03  Estimated total session cost   0.006 Hrs.

SYSTEM:OS  - DIALOG OneSearch
  File  55:BIOSIS PREVIEWS(R)  1985-1997/Aug W4
        (c) 1997 BIOSIS
  File  72:EMBASE  1985-1997/Aug W3
        (c) 1997 Elsevier Science B.V.
  File 154:MEDLINE(R)  1985-1997/Oct W4
        (c) format only 1997 Knight-Ridder Info
  File 399:CA SEARCH(R)  1967-1997/UD=12709
        (c) 1997 American Chemical Society
*File 399: Use is subject to the terms of your user/customer agreement.
For format prices, including formats 6 & 8, see HELP RATES 399.
  File 351:DERWENT WPI  1963-1997/UD=9734;UP=9731;UM=9728
        (c)1997 Derwent Info Ltd
*File 351: Excluded from Web promotion.  OnTap file 280 is reloaded.
See HELP FAQ 351 for reload info. British Apps faster - HELP NEWS 351.

      Set  Items  Description
      ---  -----  -----------
? s (cd4 or cd8) and (non(w)deplet? or nondeplet?) and antibod?

Processing
          93850  CD4
          55688  CD8
        2593371  NON
         152783  DEPLET?
            252  NON(W)DEPLET?
            358  NONDEPLET?
         977382  ANTIBOD?
      S1    192  (CD4 OR CD8) AND (NON(W)DEPLET? OR NONDEPLET?) AND
                 ANTIBOD?
? rd s1

>>>Duplicate detection is not supported for File 351.

>>>Records from unsupported files will be retained in the RD set.
...examined 50 records  (50)
...examined 50 records  (100)
...examined 50 records  (150)
...completed examining records
      S2      90  RD S1 (unique items)
? s s2 and human?

Processing
             90  S2
        9073718  HUMAN?
      S3     32  S2 AND HUMAN?
? t s3/7/all


 3/7/1     (Item 1 from file: 55)
DIALOG(R)File  55:BIOSIS PREVIEWS(R)
```

13658881 BIOSIS Number: 99658881

A **humanized** form of a **CD4**-specific monoclonal **antibody** exhibits decreased antigenicity and prolonged plasma half-life in rhesus monkeys while retaining its unique biological and antiviral properties

Reimann K A; Lin W; Bixler S; Browning B; Ehrenfels B N; Lucci J; Miatkowski K; Olson D; Parish T H; Rosa M D; Oleson F B; Hsu Y M; Padlan E A; Letvin N L; Burkly L C

Division Viral Pathogenesis, Beth Israel Deaconess Med. Cent., RE-113, 330 Brookline Ave., Boston, MA 02215, USA

AIDS Research and Human Retroviruses 13 (11). 1997. 933-943.

Full Journal Title: AIDS Research and Human Retroviruses

ISSN: 0889-2229

Language: ENGLISH

Print Number: Biological Abstracts Vol. 104 Iss. 005 Ref. 067280

Certain monoclonal **antibodies** (MAbs) directed against **CD4** can efficiently block HIV-1 replication in vitro. To explore **CD4**-directed passive immunotherapy for prevention or treatment of AIDS virus infection, we previously examined the biological activity of a **nondepleting** **CD4**-specific murine MAb, mu5A8. This MAb, specific for domain 2 of **CD4**, blocks HIV-1 replication at a post-gp120-**CD4** binding step. When administered to normal rhesus monkeys, all **CD4**+ target cells were coated with **antibody** , yet no cell clearance or measurable immunosuppression occurred. However, strong anti-mouse Ig responses rapidly developed in all monkeys. In the present study, we report a successfully **humanized** form of mu5A8 (hu5A8) that retains binding to both **human** and monkey **CD4** and anti-AIDS virus activity. When administered intravenously to normal rhesus monkeys, hu5A8 bound to all target **CD4**+ cells without depletion and showed a significantly longer plasma half-life than mu5A8. Nevertheless, an anti-hu5A8 response directed predominantly against V region determinants did eventually appear within 2 to 4 weeks in most animals. However, when hu5A8 was administered to rhesus monkeys chronically infected with the simian immunodeficiency virus of macaques, anti-hu5A8 **antibodies** were not detected. Repeated administration of hu5A8 in these animals resulted in sustained plasma levels and **CD4**+ cell coating with **humanized antibody** for 6 weeks. These studies demonstrate the feasibility of chronic administration of **CD4**-specific MAb as a potential means of treating or preventing HIV-1 infection.

3/7/2 (Item 2 from file: 55)

DIALOG(R)File 55:BIOSIS PREVIEWS(R)

13627855 BIOSIS Number: 99627855

The immunological and pharmacodynamic effects of a **humanised** **non-depleting** anti-**CD4** monoclonal **antibody** (mAb) in rheumatoid arthritis (RA)

Choy E H S; Connolly D J A; Regan T; Manna V K; Rapson N; Kingsley G H; Panayi G S; Johnston J M

Glaxo Wellcome, Beckenham, London, UK

British Journal of Rheumatology 36 (SUPPL. 1). 1997. 185.

Full Journal Title: XIVth Annual General Meeting of the British Society of Rheumatology, Harrogate, England, UK, April 23-25, 1997. British Journal of Rheumatology

ISSN: 0263-7103

Language: ENGLISH

Print Number: Biological Abstracts/RRM Vol. 049 Iss. 008 Ref. 134420

3/7/3 (Item 3 from file: 55)

DIALOG(R)File 55:BIOSIS PREVIEWS(R)

13627731 BIOSIS Number: 99627731
The clinical effect of a by **humanised non-depleting** anti-**CD4** monoclonal **antibody** (mAb) in rheumatoid arthritis (RA)
Panayi G S; Chov E H S; Connolly D J A; Manna V K; Regan T; Rapson N; Kingsley G H; Johnston J M
Rheumatology Unit, Guy's Hosp., UMDS, London, UK
British Journal of Rheumatology 36 (SUPPL. 1). 1997. 122.
Full Journal Title: XIVth Annual General Meeting of the British Society of Rheumatology, Harrogate, England, UK, April 23-25, 1997. British Journal of Rheumatology
ISSN: 0263-7103
Language: ENGLISH
Print Number: Biological Abstracts/RRM Vol. 049 Iss. 008 Ref. 134296

3/7/4 (Item 4 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

13402315 BIOSIS Number: 99402315
T cell hypothesis in rheumatoid arthritis (RA) tested by **humanised non-depleting** anti-**CD4** monoclonal **antibody** (mAb)
treatment I: Suppression of disease activity and acute phase response
Panayi G S; Choy E H S; Connolly D J A; Manna V K; Regan T; Rapson N; Kingsley G H; Johnston J M
Rheumatology Unit, Guy's Hosp., UMDS, London, UK
Immunology 89 (SUPPL. 1). 1996. 92.
Full Journal Title: Joint Congress of the British Society for Immunology and the Biochemical Society, Harrogate, England, UK, December 10-13, 1996. Immunology
ISSN: 0019-2805
Language: ENGLISH
Print Number: Biological Abstracts/RRM Vol. 049 Iss. 003 Ref. 048954

3/7/5 (Item 5 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

13402314 BIOSIS Number: 99402314
T cell hypothesis in rheumatoid arthritis (RA) tested by **humanised non-depleting** anti-**CD4** monoclonal **antibody** (mAb)
treatment II: Clinical activity is related to pharmacodynamic effects
Choy E H S; Connolly D J A; Regan T; Manna V K; Rapson N; Kingsley G H; Panayi G S; Johnston J M
Rheumatology Unit, Guy's Hosp., UMDS, London, UK
Immunology 89 (SUPPL. 1). 1996. 92.
Full Journal Title: Joint Congress of the British Society for Immunology and the Biochemical Society, Harrogate, England, UK, December 10-13, 1996. Immunology
ISSN: 0019-2805
Language: ENGLISH
Print Number: Biological Abstracts/RRM Vol. 049 Iss. 003 Ref. 048953

3/7/6 (Item 6 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

13224264 BIOSIS Number: 99224264
T cell hypothesis in rheumatoid arthritis (RA) tested by **humanized non-depleting** anti-**CD4** monoclonal **antibody** (mAb)
treatment III: Immunological effects
Connolly D J A; Choy E H S; Rapson N; Regan T; Kingsley G H; Johnston J M

; Panayi G S
Rheumatol. Unit, Guy's Hosp., UMDS, London, UK
Arthritis & Rheumatism 39 (9 SUPPL.). 1996. S245.
Full Journal Title: 60th National Scientific Meeting of the American College of Rheumatology and the 31st National Scientific Meeting of the Association of Rheumatology Health Professionals, Orlando, Florida, USA, October 18-22, 1996. Arthritis & Rheumatism
ISSN: 0004-3591
Language: ENGLISH
Print Number: Biological Abstracts/RRM Vol. 048 Iss. 011 Ref. 203385

3/7/7 (Item 7 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

13224263 BIOSIS Number: 99224263
T cell hypothesis in rheumatoid arthritis (RA) tested by **humanized non-depleting** anti-**CD4** monoclonal **antibody** (mAb) treatment II: Clinical activity is related to pharmacodynamic effects
Choy E H S; Connolly D J A; Regan T; Manna V K; Rapson N; Kingsley G H; Panayi G S; Johnston J M
Rheumatol. Unit, Guy's Hosp., UMDS, London, UK
Arthritis & Rheumatism 39 (9 SUPPL.). 1996. S244.
Full Journal Title: 60th National Scientific Meeting of the American College of Rheumatology and the 31st National Scientific Meeting of the Association of Rheumatology Health Professionals, Orlando, Florida, USA, October 18-22, 1996. Arthritis & Rheumatism
ISSN: 0004-3591
Language: ENGLISH
Print Number: Biological Abstracts/RRM Vol. 048 Iss. 011 Ref. 203384

3/7/8 (Item 8 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

13224262 BIOSIS Number: 99224262
T cell hypothesis in rheumatoid arthritis (RA) tested by **humanized non-depleting** anti-**CD4** monoclonal **antibody** (mAb) treatment I: Suppression of disease activity and acute phase response
Panayi G S; Choy E H S; Connolly D J A; Regan T; Manna V K; Rapson N; Kingsley G H; Johnston J M
Rheumatol. Unit, Guy's Hosp., UMDS, London, UK
Arthritis & Rheumatism 39 (9 SUPPL.). 1996. S244.
Full Journal Title: 60th National Scientific Meeting of the American College of Rheumatology and the 31st National Scientific Meeting of the Association of Rheumatology Health Professionals, Orlando, Florida, USA, October 18-22, 1996. Arthritis & Rheumatism
ISSN: 0004-3591
Language: ENGLISH
Print Number: Biological Abstracts/RRM Vol. 048 Iss. 011 Ref. 203383

3/7/9 (Item 9 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

13223537 BIOSIS Number: 99223537
Results of a placebo-controlled multicenter trial using a primatized **non-depleting**, anti-**CD4** monoclonal **antibody** in the treatment of rheumatoid arthritis
Levy R; Weisman M; Wisenhutter C; Yocum D; Schnitzer T; Goldman A; Schiff M; Leiden B F; Solinger A; MacDonald B; Lipani J
Olympia, WA 98502, USA

Arthritis & Rheumatism 39 (9 SUPPL.). 1996. S122.
Full Journal Title: 60th National Scientific Meeting of the American College of Rheumatology and the 31st National Scientific Meeting of the Association of Rheumatology Health Professionals, Orlando, Florida, USA, October 18-22, 1996. Arthritis & Rheumatism
ISSN: 0004-3591
Language: ENGLISH
Print Number: Biological Abstracts/RRM Vol. 048 Iss. 011 Ref. 202658

3/7/10 (Item 10 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

13031632 BIOSIS Number: 99031632
Immunological markers of response in a multi-dose protocol 7002 using an immunomodulating, **non-depleting** Primatized anti-**CD4** monoclonal **antibody** in rheumatoid arthritis (RA)
Solinger A; Paxton H; Wey K; Yocum D
IDEC Pharmaceuticals, San Diego, CA 92121, USA
FASEB Journal 10 (6). 1996. A1314.
Full Journal Title: Joint Meeting of the American Society for Biochemistry and Molecular Biology, the American Society for Investigative Pathology and the American Association of Immunologists, New Orleans, Louisiana, USA, June 2-6, 1996. FASEB Journal
ISSN: 0892-6638
Language: ENGLISH
Print Number: Biological Abstracts/RRM Vol. 048 Iss. 007 Ref. 125368

3/7/11 (Item 11 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

12165809 BIOSIS Number: 98765809
Immunological markers of response in a multi-dose protocol 7002 using an immunomodulating, **non-depleting** primatized-TM anti-**CD4** monoclonal **antibody** in rheumatoid arthritis (RA)
Solinger A; Paxton H; Wey K; Yocum D
IDEC Pharmaceuticals, San Diego, CA 92121, USA
FASEB Journal 10 (3). 1996. A442.
Full Journal Title: Experimental Biology 96, Part II, Washington, D.C., USA, April 14-17, 1996. FASEB Journal
ISSN: 0892-6638
Language: ENGLISH
Print Number: Biological Abstracts/RRM Vol. 048 Iss. 005 Ref. 082598

3/7/12 (Item 12 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

11935571 BIOSIS Number: 98535571
Modulation of mitogen and recall antigen proliferation by a **non-depleting**, anti-**CD4** monoclonal **antibody**: Results of a multi-dose study
Yocum D E; Mararescu M; Soundararaian D; Nordensson K; Solinger A M; Lipani J
Univ. Ariz., Tucson, AZ 85724, USA
Arthritis & Rheumatism 38 (9 SUPPL.). 1995. S280.
Full Journal Title: 59th National Scientific Meeting of the American College of Rheumatology and the 30th National Scientific Meeting of the Association of Rheumatology Health Professionals, San Francisco, California, USA, October 21-26, 1995. Arthritis & Rheumatism
ISSN: 0004-3591

Language: ENGLISH
Print Number: Biological Abstracts/RRM Vol. 047 Iss. 012 Ref. 205446

3/7/13 (Item 13 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

11935007 BIOSIS Number: 98535007
Treating rheumatoid arthritis with a **non-depleting** anti-**CD4** monoclonal **antibody** (MAb)
Moreland L W; Bucy R P; Knowles R W; Wacholtz M C; Haverty T P; Koopman W J
Univ. Alabama at Birmingham, Birmingham, AL, USA
Arthritis & Rheumatism 38 (9 SUPPL.). 1995. S186.
Full Journal Title: 59th National Scientific Meeting of the American College of Rheumatology and the 30th National Scientific Meeting of the Association of Rheumatology Health Professionals, San Francisco, California, USA, October 21-26, 1995. Arthritis & Rheumatism
ISSN: 0004-3591
Language: ENGLISH
Print Number: Biological Abstracts/RRM Vol. 047 Iss. 012 Ref. 204882

3/7/14 (Item 14 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

11935003 BIOSIS Number: 98535003
Results of a multi-dose protocol 7002 using an immunomodulating, **non-depleting** PRIMATIZED anti-**cD4** monoclonal **antibody** in rheumatoid arthritis (RA)
Kaine J; Solinger A; Yocum D; Lipani J; Klas P; Tesser J; Wiesenhutter C; O'Sullivan F; Shuman S; Rigby W
Sarasota Arthritis Center, Sarasota, FL 34239, USA
Arthritis & Rheumatism 38 (9 SUPPL.). 1995. S185.
Full Journal Title: 59th National Scientific Meeting of the American College of Rheumatology and the 30th National Scientific Meeting of the Association of Rheumatology Health Professionals, San Francisco, California, USA, October 21-26, 1995. Arthritis & Rheumatism
ISSN: 0004-3591
Language: ENGLISH
Print Number: Biological Abstracts/RRM Vol. 047 Iss. 012 Ref. 204878

3/7/15 (Item 15 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

11922318 BIOSIS Number: 98522318
Therapeutic monoclonal **antibodies**
Choy E H S; Panayi G S; Kingsley G H
Rheumatol. Unit, Div. Medicine, UMDS, 4th Floor, Hunt's House, Guy's Hospital, St. Thomas Street, London SE1 9RT, UK
British Journal of Rheumatology 34 (8). 1995. 707-715.
Full Journal Title: British Journal of Rheumatology
ISSN: 0263-7103
Language: ENGLISH
Print Number: Biological Abstracts Vol. 100 Iss. 011 Ref. 173175
Monoclonal **antibodies** have been used extensively over the last few years in clinical trials of rheumatoid arthritis (RA). Not only are they potential therapeutic agents, but they are also useful probes into the immunopathogenesis of RA. Anti-tumour necrosis factor alpha (TNF-alpha) monoclonal **antibodies** have been shown to be clinically efficacious. Although they produced rapid disease amelioration, the duration of clinical

improvement was limited to 4-6 weeks. Re-treatments were again effective but long-term studies are required to assess their therapeutic role in RA. So far, the therapeutic effects of lymphocyte-depleting **antibodies** have been disappointing. From the data, it is clear that synovial lymphocytes are more difficult to eliminate than peripheral blood lymphocytes and it is likely that in order to delete all synovial lymphocytes, high doses of depleting **antibodies** will be required which could lead to severe immunosuppression. Hence, lymphocyte depletion may not be a feasible therapeutic strategy. However, there are a number of clinical trials currently underway attempting to inhibit **CD4** lymphocyte function by **non-depleting antibodies** . In animal models of RA, such **antibodies** have been shown to induce long-term disease remission. Another possibility is to combine several monoclonal **antibodies** in order to induce disease remission in RA. This strategy has been used in murine collagen-induced arthritis in which a combination of anti-**CD4** and anti-TNF-alpha monoclonal **antibodies** was shown to be synergistic.

3/7/16 (Item 16 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

11760328 BIOSIS Number: 98360328
Activation of **CD4**+ T cells in the presence of a **nondepleting** monoclonal **antibody** to **CD4** induces a Th2-Type response in vitro
Stumbles P; Mason D
MRC Cellular Immunol. Unit, Sir William Dunn Sch. Pathol., University Oxford, South Parks Rd., Oxford OX1 3RE, UK
Journal of Experimental Medicine 182 (1). 1995. 5-13.
Full Journal Title: Journal of Experimental Medicine
ISSN: 0022-1007
Language: ENGLISH
Print Number: Biological Abstracts Vol. 100 Iss. 004 Ref. 052166
In vitro experiments using purified rat **CD4**+ T cells in primary and secondary mixed leukocyte cultures (MLC) have been carried out to explore the mechanism of inhibition of cell-mediated autoimmune disease in the rat by a **nondepleting** monoclonal **antibody** (mAb) to **CD4**. Previous work has shown that W3/25, a mouse anti-rat **CD4** mAb of immunoglobulin G1 isotype, completely prevents the development of the paralysis associated with experimental allergic encephalomyelitis (EAE) in Lewis rats, but does so without eliminating the encephalitogenic T cells. The in vitro experiments described in this study have shown that when **CD4**+ T cells were activated in the presence of the anti-**CD4** mAb in a primary MLC, the synthesis of interferon (IFN) gamma, but not interleukin (IL) 2, was completely inhibited. After secondary stimulation, now in the absence of the mAb, the synthesis of IL-4 and IL-13 mRNA was greatly enhanced compared with that observed from **CD4**+ T cells derived from primary cultures in which the mAb was omitted. As IL-4 and IL-13 are known to antagonize cell-mediated immune reactions, and as EAE is cell-mediated disease, the data suggest that the W3/25 mAb controls EAE by modifying the cytokine repertoire of T cells that respond to the encephalitogen. The capacity for the mAb to suppress IFN-gamma synthesis provides, in part, an explanation for this change in cytokine production. These findings are discussed in terms of what is known of the factors that determine which cytokine genes are expressed on T cell activation. Possible implications for the evolution of T cell responses in **human** immunodeficiency virus infection are also discussed.

3/7/17 (Item 17 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

11345669 BIOSIS Number: 97545669

Immunological approach to inhibit formation of anti-**antibodies** to allo- and xenogeneic anti-T cell immunoglobulin
Mysliwietz J; Thierfelder S; Mocikat R; Kremmer E
GSF, Inst. Immunol., Marchioninistr. 25, D-81377 Muenchen, GER
European Journal of Immunology 24 (10). 1994. 2323-2328.
Full Journal Title: European Journal of Immunology
ISSN: 0014-2980
Language: ENGLISH
Print Number: Biological Abstracts Vol. 098 Iss. 012 Ref. 163292

Inhibitory anti-**antibodies** induced in patients by xenogeneic or even by **humanized** anti-T cell **antibodies** remain an unresolved problem. Mice also produce anti-**antibodies** following injection of xeno- or allogeneic anti-T cell **antibodies** . Here we report a principle based on sequentially applied anti-T cell **antibodies** generated in different species, which results in suppressed anti-**antibody** formation and prolonged immunosuppression. Thus, a single priming injection in mice of mouse (MmT1 or MmT5 differing by idiotype only) or of rat (RmT1) anti-mouse Thy-1 monoclonal **antibodies** (mAb) or of rat anti-mouse L3T4 + Ly-2 (RmCD4 + **CD8**) mAb suppressed anti-**antibody** formation against subsequent booster injections of one of the above **antibodies**, provided that they differed in species origin from the priming **antibody** . Correspondingly, a sixfold and longer prolongation of 50 % survival of fully mismatched skin grafts was observed. Less or no anti-**antibody** suppression and little prolongation of graft survival was obtained if the 'first' and the 'second' (and following) **antibody** injections were of the same species, differing by iso- or idiotype only. Finally, the suppressive principle did not manifest itself at all if the initial **antibody** injection included both the first and second **antibody** . These findings are discussed with reference to earlier studies on hapten/carrier effects as well as on immunosuppression attributed to '**non-depleting**' rat anti-**CD4**/**CD8** T cell **antibodies**.

3/7/18 (Item 18 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

10805769 BIOSIS Number: 97005769
T-cell recognition of a cross-reactive antigen(s) in erythrocytic stages of Plasmodium falciparum and Plasmodium yoelii: Inhibition of parasitemia by this antigen(s)
Lucas B; Engels A; Camus D; Haque A
Centre Immunol., Biol. Parasitaire, Inst. Pasteur, 59019 Lille, FRA
Infection and Immunity 61 (11). 1993. 4863-4869.
Full Journal Title: Infection and Immunity
ISSN: 0019-9567
Language: ENGLISH
Print Number: Biological Abstracts Vol. 097 Iss. 001 Ref. 005267

In the current study, we investigated the presence of a cross-reactive antigen(s) in the erythrocyte stage from Plasmodium yoelii (265 BY strain) and Plasmodium falciparum through recognition by T cells primed in vivo with antigens from each of these parasites. BALB/c mice are naturally resistant to P. falciparum but are susceptible to P. yoelii infection. Mice that had recovered from P. yoelii primary infection became resistant to a second infection. A higher in vitro proliferative response to a soluble blood stage preparation of P. falciparum was observed in splenic cells from immune animals than in those from mice with a patent P. yoelii infection. The antigen-induced proliferative response was enhanced when animals were exposed to a secondary infection. Animals exposed to a challenge infection were treated with anti-**CD4** or anti-**CD8** monoclonal **antibodies** to deplete the corresponding subset of T cells. There was a marked diminution in P. falciparum antigen-induced proliferative response in the total splenic cell populations from **CD8**-depleted but not from **CD4**-depleted mice. In **CD8**-depleted and **nondepleted**

animals, the antigen-induced proliferation in the total cell populations was markedly lower than in the T-cell-rich populations, indicating inhibitory activities of B cells and/or macrophages. There was no such difference in the stimulation between total and T-enriched cell populations from **CD4** -depleted animals. Flow cytometry analysis demonstrated the presence of an almost equal percentage of **CD8**+ (59.6%) and **CD4**+ (64%) T cells in the spleen preparations following in vivo depletion of **CD4**- and **CD8**-bearing T cells, respectively. When cultured with P. yoelii blood stage antigen, splenocytes from animals immunized with P. falciparum antigen displayed a significant proliferative response which was markedly diminished by treatment with anti-Thy-1.2 **antibody** plus complement. Animals immunized with P. falciparum antigen and then challenged with P. yoelii blood stage parasites displayed about a 50% lower level of parasitemia. These results demonstrated the existence of a cross-reactive antigen(s) between a murine and a **human** Plasmodium species, as determined from both in vivo and in vitro biological assays, and indicated the reactivity of mainly **CD8** + T cells with this antigen.

3/7/19 (Item 19 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

8095291 BIOSIS Number: 91016291
RESISTANCE TO INFECTION BY HIV-1 OF PERIPHERAL BLOOD MONONUCLEAR CELLS FROM HIV-1-INFECTED PATIENTS IS PROBABLY MEDIATED BY NEUTRALIZING **ANTIBODIES**

TREMBLAY M; NUMAZAKI K; LI X; GORNITSKY M; HISCOTT J; WAINBERG M A
MCGILL AIDS CENTRE JEWISH GENERAL HOSP., 3755 COTE STE-CATHERINE ROAD, MONTREAL, QUEBEC H3T 1E2, CAN.

J IMMUNOL 145 (9). 1990. 2896-2901. CODEN: JOIMA
Full Journal Title: Journal of Immunology
Language: ENGLISH

We have investigated whether PBMC of HIV-1-seropositive subjects are as susceptible to in vitro infection by HIV-1 as are PBMC from seronegative controls. Accordingly, stimulated PBMC from 19 HIV-1-infected subjects were inoculated with four different variants of HIV-1. None of these cultures produced either detectable quantitites of viral reverse transcriptase activity or p24 Ag following inoculation with HIV-1. In contrast, in five of six cases in which these PBMC were depleted of B cells by **antibody** plus complement prior to viral inoculation, the presence of viral reverse transcriptase and p24 Ag was detected. The presence of normal levels of **CD4** Ag at the surface of the **CD4**+ cells in these populations was established by flow cytometry. Analysis by an immunoblot assay revealed that anti-HIV **antibodies** were present in the sera obtained from these infected donors; in addition, 7 of 10 culture fluids derived from the **nondepleted** PBMC were shown to contain virus-neutralizing **antibodies** . Cultures which were depleted of B cells did not contain detectable levels of antiviral **antibodies** . Confirmation that the virus produced by the PBMC which had been depleted of B cells was of the strain used to infect the cultures, rather than that which initially caused patient infection, was provided on the basis of differential susceptibility to **antibody** neutralization. These results suggest that **antibodies** produced by B cells in cultures of PBMC from seropositive donors may restrict infection by HIV-1 of such cultures under laboratory conditions.

3/7/20 (Item 20 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

7083977 BIOSIS Number: 88006722
ENDOGENOUSLY GENERATED ACTIVATED KILLER CELLS CIRCULATE AFTER AUTOLOGOUS

AND ALLOGENEIC MARROW TRANSPLANTATION BUT NOT AFTER CHEMOTHERAPY
REITTIE J E; GOTTLIEB D; HESLOP H E; LEGER O; DEXLER H G; HAZLEHURST G; HOFFBRAND A V; PRENTICE H G; BRENNER M K
DEP. HAEMATOL., ROYAL FREE HOSP., POND ST., LONDON, NW3, UK.
BLOOD 73 (5). 1989. 1351-1358. CODEN: BLOOA
Full Journal Title: Blood
Language: ENGLISH
After marrow transplantation, major histocompatibility complex (MHC)-unrestricted natural killer (NK) lymphocytes are among the first cells to appear in the circulation. After T-cell-depleted bone marrow transplantation (TD-BMT), these cells have an activated pattern of target cell killing; they also secrete lymphokines including .gamma.-interferon (.gamma.-IFN), interluekin-2 (IL-2), and tumor necrosis factor (TNF) and may have a significant role as a primary defense against viral reactivation and in the elimination of residual host malignancy. We studied 43 patients with hematologic malignancy, treated by allogeneic TD-BMT, autologous **nondepleted** BMT, or chemotherapy alone to investigate (a) the mechanisms underlying the generation of these activated killer cells, (b) the range of conditions under which they are produced, and (c) their surface phenotype. We showed that .gamma.-IFN-secreting activated killer cells with the capacity to kill MHC-nonidentical NK-resistant targets are generated 4 to 6 weeks after either allogeneic TD-BMT or autologous BMT but do not appear after treatment with chemotherapy. Production therefore is not owing to T-cell depletion per se or to host donor alloreactivity, nor is it caused by stimulation by alloantigens contained in blood product support since no significant difference exists between allograft and chemotherapy patients in the number of units of blood platelet support given in the posttreatment period. Because most patients had no evidence of stimulation from virus reactivation/infection, the phenomenon of activation therefore appears to represent posttransplant immune disregulation following repopulation of the host immune system with lymphoid subsets derived exclusively from blood and marrow. Activated killing is predominantly mediated by the CD16+ CD3- subset, but substantial activity remains in the CD16- CD3+ cell fraction. Monoclonal **antibodies** (MoAbs) that block interaction with class-I MHC molecules at the level of target cell (W6/32 anti-HLA class I) or effector cell (**CD8**) do not inhibit killing by CD16- CD3+ cells. Activated killer cells may contribute to the lower risk of relapse after marrow transplantation as compared with intensive chemotherapy.

3/7/21 (Item 21 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

5856041 BIOSIS Number: 83118348
A COMPARATIVE STUDY OF T-CELL DEPLETED AND **NON-DEPLETED** MARROW TRANSPLANTATION FOR HEMATOLOGICAL MALIGNANCY
ATKINSON K; ASHBY M; BIGGS J; CONCANNON A; COOLEY M; DODDS A; FARRELLY H; MORGAN G; O'FLAHERTY E; ET AL
BONE MARROW TRANSPLANT. UNIT, ST. VICENT'S HOSP., DARLINGHURST, NSW 2010.
AUST N Z J MED 17 (1). 1987. 16-23. CODEN: ANZJB
Full Journal Title: Australian and New Zealand Journal of Medicine
Language: ENGLISH
Sixteen patients with hematological malignancy received cyclophosphamide (120 mg/kg), fractionated total body irradiation (12 Gy), oral cyclosporin, and an HLA-identical sibling marrow transplant depleted of T cells by incubation with the monoclonal **antibody** antiHuLy-m1 (CD2) and rabbit complement with (five patients) or without (11 patients) anti-HuLy-m8 (**CD8**). These 16 patients were compared historically to 84 patients with hematological malignancy receiving cyclophosphamide (120 mg/kg), fractionated total body irradiation (12 or 14 Gy), oral cyclosporin, and unmanipulated HLA-identical sibling marrow, for parameters of engraftment and graft-versus-host disease (GVHD). Graft failure occurred in one of the 16 T-cell depleted recipients and in one of the 84 **non-depleted**

recipients. Engraftment was slightly but significantly slower in the T-cell depleted group and bacterial infections significantly more frequent and severe than in the unmanipulated group. There was a suggestion that the severity of acute GVHD was reduced in those receiving T depleted marrow. Randomized trials will be necessary to determine if marrow T-cell depletion results in superior long-term leukemia-free survival.

3/7/22 (Item 1 from file: 72)
DIALOG(R)File 72:EMBASE

9787616 EMBASE No: 95351540
T-cell regulation
Choy E.H.S.; Kingsley G.H.; Panayi G.S.
UMDS, Rheumatology Unit, Guy's Hospital, St Thomas Street, London SE1 9RT United Kingdom
Bailliere's Clinical Rheumatology (United Kingdom) , 1995, 9/4 (653-671)
CODEN: BCRHE ISSN: 0950-3579
LANGUAGES: English SUMMARY LANGUAGES: English
There is considerable evidence to implicate T cells in the pathogenesis of rheumatoid arthritis (RA). They initiate and sustain inflammation and therefore are attractive targets for immunotherapy. Several strategies targeting T cells have been tried in RA. The use of monoclonal **antibodies** to deplete T cells has been used extensively but with little success. Studies have shown that T cell depleting **antibodies** produce profound peripheral blood lymphopenia but they are less effective in depleting lymphocytes in the joint. Since clinical efficacy is likely to depend on depleting almost all synovial lymphocytes, high doses of monoclonal **antibodies** would have to be given. However, the invariably severe peripheral blood lymphopenia induced by such a regimen is likely to result in profound immunosuppression. Therefore, this strategy has been abandoned and recent attempts have been made to induce tolerance in RA. In animal models of RA, treatment with high dose **non-depleting** anti-**CD4** monoclonal **antibody** protects them from arthritis induced by injection of streptococcal cell wall. In addition, it leads to a state of anergy which protects the animals from arthritis induction without further treatment with anti-**CD4** monoclonal **antibody**. This is currently being used in clinical trials of RA. Other tolerance inducing treatment strategies include T cell or T cell receptor vaccination and oral tolerance. The former is particularly difficult since the rheumatoid arthritogenic antigen and the pathogenic T cell remain unknown. The latter has shown promise in placebo controlled trials although the ideal dosage remains unknown. The mechanism of action of oral tolerance involves either immunosuppressive T cell cytokines, T cell anergy or depletion.

3/7/23 (Item 2 from file: 72)
DIALOG(R)File 72:EMBASE

9532547 EMBASE No: 95106020
Anti-**CD4** monoclonal **antibody** immune intervention in patients with newly diagnosed Type I (insulin-dependent) diabetes mellitus
Hehmke B.; Kuttler B.; Laube F.; Gens E.; Michaelis D.; Hahn H.-J.; Schulze-Koops H.; Emmrich F.
Institute Diabetes 'Gerhardt Katsch', Dept Experimental Clin Endocrinology, D-17495 Karlsburg Germany
Diabetes, Nutrition and Metabolism - Clinical and Experimental (Italy) , 1994, 7/5 (273-280) CODEN: DNMEE ISSN: 0394-3402
LANGUAGES: English SUMMARY LANGUAGES: English
A randomized controlled trial was conducted to determine if anti-**CD4** monoclonal **antibody** (mAb) together with prednisolone immunotherapy could improve or prolong clinical remission in children with newly diagnosed insulin-dependent (Type I) diabetes mellitus. Eleven

children entered the trial within 1 week of initiation of insulin therapy and were followed-up for 1 year. Five of them were assigned to the treatment group, the control group comprised 6 children receiving insulin therapy only. Baseline clinical and metabolic data did not differ significantly in the two groups of patients. In addition to insulin therapy, the treatment group received infusions of anti-**CD4** mAb MAX.16H5 at a dose of 0.5 mg/kg/day for 5 consecutive days plus daily prednisolone at a dose of 1.0 mg/kg/day (5 days i.v., 5 days oral). Moderate depletion of **CD4**+ blood cells and marked decreases of the mean **CD4** antigen density on the surfaces of **non-depleted** **CD4**+ cells occurred 24h after the first anti-**CD4** mAb/prednisolone infusion in all treated children. Complete reappearance of **CD4**+ blood cells was seen at 3 months of follow-up whereas **CD4**+ antigen expression rapidly regained pretreatment levels within 2 weeks after termination of immunotherapy. Only 2 patients developed low levels of **human** anti-mouse immunoglobulin **antibodies** (HAMAs) 3-12 weeks after they had received mouse mAb 16H5. Both groups of patients displayed elevated levels of activated T lymphocytes (HLA-DR+CD3+) that were not affected by immunotherapy. Clinically, insulin requirement and glycated hemoglobin (HbA1) concentrations did not differ among the patient groups, neither at diagnosis nor at quarterly intervals during the 1-year follow-up. Fasting levels of plasma C-peptide increased in 3 patients immediately after administration of anti-**CD4** mAb (day 6), but this initial improvement of residual beta-cell function was no longer detectable after day 10. Thereafter insulin requirement and fasting C peptide did not differ between the two groups of patients. Plasma C-peptide achieved levels of about 300 pmol/l. Only in one patient who also developed the highest HAMA response plasma C-peptide rose to about 700 pmol/l at 6 months of follow-up. In this patient (fm, 8yr), improvement of residual beta-cell function was accompanied by a gradual decrease of the insulin requirement from 0.81 IU/kg/day at clinical diagnosis down to 0.26 IU/kg/day by the end of the 1-year post-treatment observation period. In the present study, apparently all patients have benefited from intensified insulin therapy initiated immediately after clinical diagnosis and from maintenance of strict metabolic control during follow-up. However, a single course of anti-**CD4** /prednisolone immunotherapy does not generally result in additional clinical benefits.

3/7/24 (Item 3 from file: 72)
DIALOG(R)File 72:EMBASE

8675097 EMBASE No: 92355607
Anti-**CD4** monoclonal **antibodies** in therapy: Creation of nonclassical tolerance in the adult
Shizuru J.A.; Alters S.E.; Fathman C.G.
Stanford Univ. School of Medicine, Div. of Rheumatology and Immunology, Stanford, CA 94305 USA
IMMUNOL. REV. (Denmark) , 1992, -/129 (105-130) CODEN: IMRED ISSN: 0105-2896 ADONIS ORDER NUMBER: 010528969200046X
LANGUAGES: English SUMMARY LANGUAGES: English
We have described the studies from our laboratory which demonstrate that depleting anti-**CD4** mAb induce tolerance to foreign antigens in adult, euthymic animals. Further, we have proposed that such tolerance occurs as a result of new thymic migrants encountering antigens in the periphery. However, these conclusions can be considered only partial since we (Song et al. in press) and others have shown that depletion of T cells per se does not permit tolerance. For example, anti-Thy-1 or anti-Lyt-1 are themselves immunosuppressive and able to deplete T cells, yet they elicit strong anti-globulin responses against themselves and do not permit tolerance to be induced either to transplants or administered soluble protein antigen. We have recently found that while the combination of anti-**CD4** and anti-**CD8** mAb allows long-term survival of allografted islets in mice, anergy in the relevant T-cell subsets was not found (in contrast to what is

found with anti-**CD4** mAb treatment alone) (Song et al. in press). In this instance, long-term survival was probably the result of changes in graft immunogeneity (i.e., migration of passenger leukocytes) since the kinetics of repopulation were much delayed in the anti-**CD4** and -**CD8** treated mice. As discussed elsewhere in this volume, interesting studies from several laboratories suggest that **non-depleting** anti-**CD4** mAb can generate unresponsiveness in a variety of systems. In reviewing the literature it is clear that the success of **non-depleting** reagents appears to be dependent upon the model system tested. For example, although depleting and **nondepleting CD4** mAb regimens produced comparable prolongation of cultured fetal pancreas allografts in mice (Charlton and Mandel), almost total elimination of circulating **CD4**+ cells did not prevent acute rejection of murine skin grafts (Auchincloss et al. 1988). This heterogeneity is not surprising given the multiple functional roles of the **CD4** molecule and the cells that bear this molecule. In addition to depletion, **antibodies** directed against **CD4** can potentially affect **CD4**+ cell function by (1) direct blockade or failure to augment the formation of the TCR-antigen/MHC ternary complex or (2) by transmitting a negative signal to the **CD4** T cell or interfering with normal signal transduction mechanisms. Undoubtedly, it is a combination of mechanisms that allows these **antibodies** their immunosuppressive effects. What can be said with certainty is that these **antibodies** will continue to be important tools for understanding the molecular and cellular basis of the immune response, and will soon emerge as invaluable therapeutic agents in the clinical arena.

3/7/25 (Item 4 from file: 72)
DIALOG(R)File 72:EMBASE

8183556 EMBASE No: 91209639
Monoclonal **antibody** therapy for the induction of transplantation tolerance
Cobbold S.P.
Division of Immunology, Cambridge University Department of Pathology, Tennis Court Road, Cambridge CB1 2QP United Kingdom
IMMUNOL. LETT. (Netherlands) , 1991, 29/1-2 (117-122) CODEN: IMLED ISSN: 0165-2478 ADONIS ORDER NUMBER: 016524789100175N
LANGUAGES: English
There are three ways in which monoclonal **antibodies** could be used to facilitate the induction of tolerance to foreign tissues after organ transplantation. First, depleting monoclonal **antibodies** could be directed against the T cells responsible, thereby reducing their number and acting to non-specifically immunosuppress the patient. This is generally not sufficient to allow tolerance induction in the T cells which repopulate the periphery. Second, depleting monoclonal **antibodies** could be used to remove donor passenger leukocytes and antigen-presenting cells from the donor organ, which may both reduce immunogenicity and increase the chance of tolerance induction. Third, **non-depleting**, but functionally blocking, monoclonal **antibodies** to T cell molecules such as **CD4** and **CD8** can allow the specific induction of transplantation tolerance in mouse models, an approach which might be applicable to man, not only for organ transplantation, but also in the treatment of autoimmune diseases. These three approaches are, in time, likely to complement each other in clinical practice. Monoclonal **antibodies** can be tailored to each approach by choosing appropriate specificities and isotypes, and further refinements can be made where necessary by making monovalent or **humanised antibodies** . The application of each of these approaches to clinical therapy is described.

3/7/26 (Item 5 from file: 72)
DIALOG(R)File 72:EMBASE

8013038 EMBASE No: 91038466

Induction of tolerance in peripheral T cells with monoclonal **antibodies**

Qin S.; Wise M.; Cobbold S.P.; Leong L.; Kong Y.-C.M.; Parnes J.R.; Waldmann H.

Division of Immunology, Department of Pathology, Cambridge University, Cambridge CB2 2QQ United Kingdom

EUR. J. IMMUNOL. (Germany, Federal Republic of) , 1990, 20/12 (2737-2745) CODEN: EJIMA ISSN: 0014-2980

LANGUAGES: English

Our goal has been to develop ways to tolerize the mature immune system to any defined antigen. In this report we show that peripheral (post-thymic) T cells of mice can become tolerant to a range of antigens (**human** and rat immunoglobulins, and bone marrow and skin grafts that differ at multiple minor transplantation antigens). In the case of **human** gamma globulin (HGG), this required that the antigen be given under the cover of a short course of **non-depleting** anti-**CD4 antibody**, while for tolerance to skin and marrow grafts anti-**CD8 antibody** was also required. Tolerance to HGG could be reinforced by repeated injections of HGG, but was lost in the absence of any further exposure to antigen. This reversal of tolerance with time was due to new T cells being exported from the thymus, as it was not observed in tolerized, adult thymectomized mice. In contrast, tolerance to marrow and skin grafts was permanent, presumably because the established grafts acted as a continuous source of antigen to reinforce the tolerant state. Tolerance could not be broken by the infusion of unprimed spleen cells and in one example (tolerance to Mls-1a) there was clear evidence that specific peripheral T cells were anergic. We propose that anergic cells may themselves participate in reinforcing the tolerant state by competing at sites of antigen presentation.

3/7/27 (Item 1 from file: 154)

DIALOG(R)File 154:MEDLINE(R)

08554040 96161423

Innovative treatment approaches for rheumatoid arthritis. T-cell regulation.

Choy EH; Kingsley GH; Panayi GS

UMDS, Rheumatology Unit, Guy's Hospital, London, UK.

Baillieres Clin Rheumatol (ENGLAND) Nov 1995, 9 (4) p653-71, ISSN 0950-3579 Journal Code: CRY

Languages: ENGLISH

Document type: JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL

There is considerable evidence to implicate T cells in the pathogenesis of rheumatoid arthritis (RA). They initiate and sustain inflammation and therefore are attractive targets for immunotherapy. Several strategies targeting T cells have been tried in RA. The use of monoclonal **antibodies** to deplete T cells have been used extensively but with little success. Studies have shown that T cell depleting **antibodies** produce profound peripheral blood lymphopenia but they are less effective in depleting lymphocytes in the joint. Since clinical efficacy is likely to depend on depleting almost all synovial lymphocytes, high doses of monoclonal **antibodies** would have to be given. However, the invariably severe peripheral blood lymphopenia induced by such a regimen is likely to result in profound immunosuppression. Therefore, this strategy has been abandoned and recent attempts have been made to induce tolerance in RA. In animal models of RA, treatment with high dose **non-depleting** anti-**CD4** monoclonal **antibody** protects them from arthritis induced by injection of streptococcal cell wall. In addition, it leads to a state of anergy which protects the animals from arthritis induction without further treatment with anti-**CD4** monoclonal **antibody**. This is

currently being used in clinical trials of RA. Other tolerance inducing treatment strategies include T cell or T cell receptor vaccination and oral tolerance. The former is particularly difficult since the rheumatoid arthritogenic antigen and the pathogenic T cell remain unknown. The latter has shown promise in placebo controlled trials although the ideal dosage remains unknown. The mechanism of action of oral tolerance involves either immunosuppressive T cell cytokines, T cell anergy or depletion. (76 Refs.)

3/7/28 (Item 2 from file: 154)
DIALOG(R)File 154:MEDLINE(R)

07419561 92368404
The forces driving autoimmune disease.
Roitt IM; Hutchings PR; Dawe KI; Sumar N; Bodman KB; Cooke A
Dept. of Immunology, University College & Middlesex School of Medicine, London, UK.
J Autoimmun (ENGLAND) Apr 1992, 5 Suppl A p11-26, ISSN 0896-8411
Journal Code: ADL
Languages: ENGLISH
Document type: JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
There are two classes of autoimmune disease, organ-specific and non-organ specific or systemic. That cells producing autoantibodies are selected by antigen is strongly suggested by the presence of mutations and high affinity **antibody** . T-cells are pivotal in all forms of autoimmunity as evidenced by the therapeutic benefit of anti-T-cell monoclonals such as anti-**CD4** , and the frequent development of high affinity IgG autoantibodies. The production of anergic T-cells by the use of **non-depleting** anti-**CD4** in the presence of antigen is discussed with particular reference to its potential for immunological intervention in autoimmune disease. It is possible to identify T-cell epitopes in organ-specific autoimmunity using pathogenic T-cell clones or hybridomas to identify the peptide sequences which are reactive. Antigen-specific therapy may ultimately be based on such peptide epitopes. The specificity of the T-cells in systemic autoimmunity is still obscure, but there is some evidence that reactivity with certain germ-line idiotypes can lead to the development of systemic autoimmunity. The possibility of stimulating B-cells specific for auto-antigens such as DNA becomes feasible if a complex of **antibody** and DNA is taken up by these specific B-cells and processed idiotype is presented to T-helpers specific for those idiotype epitopes. Evidence is presented that there may be pre-existing defects in the target organ in certain organ-specific disorders, and the evidence for a glycosylation defect in the IgG in patients with rheumatoid arthritis is explored. It is noted that the spouses of probands with rheumatoid arthritis is explored. It is noted that the spouses of probands with rheumatoid arthritis also tend to have this glycosylation defect and this raises the possibility of an effect due to an environmental factor, such as a microbial infection. Molecular mimicry of autoantigens by microbes can stimulate autoreactive cells by their cross-reactivity. It is emphasized that cross-reaction which gives rise to the priming of autoreactive T-cells could give rise to the establishment of a chronic autoimmune state. In animals with normal regulatory immune systems, such induced autoimmunity is ultimately corrected and it is only in animals where there are defects in regulation, that autoimmunity persists. Thus, there are many factors giving rise to autoimmunity, and the diseases are rightly regarded as multifactorial in origin. (22 Refs.)

3/7/29 (Item 3 from file: 154)
DIALOG(R)File 154:MEDLINE(R)

06620943 91370929
Reprogramming the immune system for tolerance with monoclonal

antibodies.

Cobbold SP; Qin SX; Waldmann H
Department of Pathology, Cambridge University, UK.

Semin Immunol (UNITED STATES) Nov 1990, 2 (6) p377-87, ISSN 1044-5323
Journal Code: A61
Languages: ENGLISH
Document type: JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL

Monoclonal **antibodies** to **CD4**, **CD8** and CD11a can be used in vivo either to deplete or functionally block T cells to create a tolerance permissive environment. Short courses of **non-depleting CD4** and **CD8 antibodies** were used to induce tolerance separately in **CD4**+ and **CD8**+ T cells either to foreign immunoglobulins, bone marrow, or skin grafts. Tolerance was obtained to minor (non-MHC) transplantation antigens without T cell depletion even in actively sensitized mice, or to MHC plus minor antigens presented directly by skin grafts using combinations of depleting followed by blockading **CD4** and **CD8 antibodies** . In all cases, tolerance was specific to the antigen/tissue given under cover of **antibody** treatment, and in one example it could be shown that T cells directed to MLS-1a had been forced into an anergic state. This induction of tolerant, anergic T cells in the periphery is able to explain many of the features associated with tolerance, not only in the model systems using foreign antigens, but also in the normal regulation of anti-self responses and its failure in autoimmune diseases. It is our new found ability to use antigen under the cover of **antibody** treatment to accurately control the pattern of tolerant T cells in vivo that we refer to by using the term 'reprogramming'. We also describe the clinical treatment of one patient with an autoimmune vasculitis based on the ideas developed from the mouse models. (47 Refs.)

3/7/30 (Item 1 from file: 351)
DIALOG(R)File 351:DERWENT WPI

011033929
WPI Acc No: 97-011853/199701
Amt. of **non-depleting** anti-**CD4 antibody** effective to induce immunological tolerance - useful to inhibit allo-graft rejection in primate subject, specifically bone marrow allo-graft
Patent Assignee: JOHNSON & JOHNSON CORP (JOHJ)
Inventor: CAVENDER D E; KNOWLES R W; THOMAS J M
Number of Countries: 069 Number of Patents: 002
Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Main IPC	Week
WO 9636359	A1	19961121	WO 96US6912	A	19960516	A61K-039/395	199701 B
AU 9657479	A	19961129	AU 9657479	A	19960516	A61K-039/395	199712

Priority Applications (No Type Date): US 95443739 A 19950518
Cited Patents: 5. journal ref.; EP 240344; WO 9109966; WO 9205274
Patent Details:

Patent	Kind	Lan	Pg	Filing Notes	Application	Patent
WO 9636359	A1	E	17			

Designated States (National): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN
Designated States (Regional): AT BE CH DE DK EA ES FI FR GB GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG

AU 9657479	A	Based on	WO 9636359

Abstract (Basic): WO 9636359 A
Amt. of a **non-depleting** anti-**CD4 antibody** (Ab), pref. a **humanised** cdr-grafted Ab, effective to induce immunological tolerance, further comprises donor bone marrow.
USE - The Ab, esp. administered in an amt. sufficient to maintain

lymphocyte **CD4** saturation (partic. 5 mg/kg) for a sufficient period to permit immunological tolerance induction, can be used to inhibit allograft rejection in a primate subject, specifically a bone marrow allograft (claimed).

Dwg.0/2

Derwent Class: B04
International Patent Class (Main): A61K-039/395
International Patent Class (Additional): C07K-016/28

3/7/31 (Item 2 from file: 351)
DIALOG(R)File 351:DERWENT WPI

009140953
WPI Acc No: 92-268391/199232
Use of single non-depleting CD4 monoclonal antibody - for treatment of insulin-dependent diabetes mellitus (IDDM), arrests loss of insulin producing cells
Patent Assignee: UNIV COLLEGE LONDON (UNLO)
Inventor: COOKE A; WALDMANN H
Number of Countries: 035 Number of Patents: 005
Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Main IPC	Week
WO 9211869	A1	19920723	WO 92GB74	A	19920114	A61K-039/395	199232 B
AU 9211647	A	19920817	AU 9211647	A	19920114	A61K-039/395	199245
			WO 92GB74	A	19920114		
EP 567490	A1	19931103	EP 92902288	A	19920114	A61K-039/395	199344
			WO 92GB74	A	19920114		
JP 6504283	W	19940519	JP 92502777	A	19920114	A61K-039/395	199424
			WO 92GB74	A	19920114		
AU 668081	B	19960426	AU 9211647	A	19920114	A61K-039/395	199624

Priority Applications (No Type Date): GB 91741 A 19910114
Cited Patents: 4. journal ref.
Patent Details:

Patent	Kind	Lan	Pg	Filing Notes	Application	Patent
WO 9211869	A1	E	19			
Designated States (National): AT AU BB BG BR CA CH DE DK ES FI GB HU JP KP KR LK LU MG MW NL NO PL RO RU SD SE US						
Designated States (Regional): AT BE CH DE DK ES FR GB GR IT LU MC NL OA SE						
AU 9211647	A			Based on		WO 9211869
EP 567490	A1	E		Based on		WO 9211869
Designated States (Regional): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE						
JP 6504283	W		5	Based on		WO 9211869
AU 668081	B			Previous Publ.		AU 9211647
				Based on		WO 9211869

Abstract (Basic): WO 9211869 A

Use of a **non-depleting CD4** monoclonal **antibody** (MAb), (A), in the prepn. of a medicament for treating insulin-dependent diabetes mellitus (IDDM) in **humans** or animals is new.

Also claimed is the treatment method using an effective, non-toxic amt.of (A); and a pharmaceutical compsn. comprising no less than (A) and a diluent or carrier.

ADVANTAGE - (A) arrests the loss of insulin-producing cells and allows regeneration of beta cells, to reverse the course of the disease. Ideally, treatment with (A) commences soon after the disease has beome potent, so the patient retains the majority of beta cells. However, even when the disease has progressed, (A) is beneficial in protecting remaining beta cells. Treatment comprises not less than 1 dose of (A) and pref. a course of several doses.

In **humans**, doses of 400 micro g-1 mg (A), esp. 5-20 mg in an otherwise healthy adult of ca. 75 kg are used. A saturating amt. of (A) is us

Dwg. 0/0

Derwent Class: B04

International Patent Class (Main): A61K-039/395

3/7/32 (Item 3 from file: 351)

DIALOG(R)File 351:DERWENT WPI

008503137

WPI Acc No: 91-007221/199101

Non-depleting CD4 and **CD8** monoclonal **antibodies** - for inducting tolerance to foreign antigens in transplant rejection, auto-immune disease, etc

Patent Assignee: COBBOLD S P (COBB-I); WALDMANN H (WALD-I); WELLCOME FOUND LTD (WELL)

Inventor: COBBOLD S P; WALDMANN H

Number of Countries: 024 Number of Patents: 013

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Main IPC	Week
WO 9015152	A	19901213				B	199101 B
PT 94214	A	19910208				B	199109
AU 9057258	A	19910107				B	199115
EP 474691	A	19920318	EP 90908270	A	19900531	B	199212
ZA 9004174	A	19920226	ZA 904174	A	19900530	B	199213
DD 296843	A5	19911219	DD 341218	A	19900531	B	199221
JP 4505919	W	19921015	JP 90508030	A	19900531	B	199248
			WO 90GB840	A	19900531		
HU 61341	T	19921230	HU 905134	A	19900531	B	199306
			WO 90GB840	A	19900531		
AU 657255	B	19950309	AU 9057258	A	19900531	B	199520
EP 474691	B1	19961113	EP 90908270	A	19900531	B	199650
			WO 90GB840	A	19900531		
DE 69029134	E	19961219	DE 629134	A	19900531	B	199705
			EP 90908270	A	19900531		
			WO 90GB840	A	19900531		
ES 2096588	T3	19970316	EP 90908270	A	19900531	B	199718
NZ 233889	A	19970624	NZ 233889	A	19900531	B	199732

Priority Applications (No Type Date): GB 8912497 A 19890531

Cited Patents: 4. journal ref.

Patent Details:

Patent	Kind	Lan	Pg	Filing Notes	Application	Patent
WO 9015152	A					
Designated States (National): AU CA FI HU JP KR US						
Designated States (Regional): AT BE CH DE DK ES FR GB IT LU NL SE						
EP 474691	A		44			
Designated States (Regional): AT BE CH DE DK ES FR GB IT LI LU NL SE						
ZA 9004174	A		57			
JP 4505919	W		19	Based on		WO 9015152
HU 61341	T			Based on		WO 9015152
AU 657255	B			Previous Publ.		AU 9057258
				Based on		WO 9015152
EP 474691	B1	E	32	Based on		WO 9015152
Designated States (Regional): AT BE CH DE DK ES FR GB IT LI LU NL SE						
DE 69029134	E			Based on		EP 474691
				Based on		WO 9015152
ES 2096588	T3			Based on		EP 474691

Abstract (Basic): WO 9015152 A

Non depleting CD4 and **CD8** monoclonal **antibodies** are claimed for use in inducing tolerance to an

antigen. The use of these **antibodies** and packs contg. them are also claimed. The prods. may also contain a depleting **CD4** monoclonal **antibody** and/or a depleting **CD8** monoclonal **antibody**.

Single dose for a **human** is 1-400mg (esp. 3-30mg) of **antibody**. Admin. is parenteral e.g. intravenous.

USE/ADVANTAGE - For producing tolerance to foreign immunoglobulins, bone marrow and skin grafts. To treat autoimmune diseases without the need for long term chemotherapy and to produce tolerance to therapeutic polypeptides such as interferon, IL-II or TNF. (44pp Dwg.No.0/13

Abstract (Equivalent): EP 474691 B

Use of a **non-depleting** anti-**CD4** monoaconal **antibody**, ie an **antibody** which causes depletion of fewer than 50% of **CD4**+ T-cells from the periphery as measured by changes in the peripheral blood lymphocyte numbers, for the manufacture of a medicament for the induction of a state of immunological tolerance to an antigen by a method which comprises administering said **non-depleting** anti-**CD4** monoclonal **antibody** to a subject together with a **non-depleting** anti-**CD8** monoclonal **antibody**, ie an **antibody** which causes depletion of fewer than 50% of **CD8**+ T-cells from the periphery as measured by changes in the peripheral blood lymphocyte numbers, to induce an immunological tolerance permissive environment within said subject by means of said **antibodies** in the presence of said antigen.

Dwg.0/11b

Derwent Class: B04; D16

International Patent Class (Main): A61K-039/395; C12P-021/08

International Patent Class (Additional): A61K-039/39; C07K-015/28;

ds

Set	Items	Description
S1	192	(CD4 OR CD8) AND (NON(W)DEPLET? OR NONDEPLET?) AND ANTIBOD?
S2	90	RD S1 (unique items)
S3	32	S2 AND HUMAN?

? t s2/3/all

2/3/1 (Item 1 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

13659285 BIOSIS Number: 99659285
A role for Th2 cytokines in the suppression of **CD8**+ T cell-mediated graft rejection
Scully R; Cobbold S P; Mellor A L; Wissing M; Arnold B; Waldmann H
Sir William Dunn Sch. Pathol., South Parks Road, Oxford OX1 3RE, UK
European Journal of Immunology 27 (7). 1997. 1663-1670.
Full Journal Title: European Journal of Immunology
ISSN: 0014-2980
Language: ENGLISH
Print Number: Biological Abstracts Vol. 104 Iss. 005 Ref. 067684

2/3/2 (Item 2 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

13658881 BIOSIS Number: 99658881
A humanized form of a **CD4**-specific monoclonal **antibody** exhibits decreased antigenicity and prolonged plasma half-life in rhesus monkeys while retaining its unique biological and antiviral properties
Reimann K A; Lin W; Bixler S; Browning B; Ehrenfels B N; Lucci J; Miatkowski K; Olson D; Parish T H; Rosa M D; Oleson F B; Hsu Y M; Padlan E A; Letvin N L; Burkly L C
Division Viral Pathogenesis, Beth Israel Deaconess Med. Cent., RE-113, 330 Brookline Ave., Boston, MA 02215, USA
AIDS Research and Human Retroviruses 13 (11). 1997. 933-943.
Full Journal Title: AIDS Research and Human Retroviruses
ISSN: 0889-2229
Language: ENGLISH
Print Number: Biological Abstracts Vol. 104 Iss. 005 Ref. 067280

2/3/3 (Item 3 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

13644851 BIOSIS Number: 99644851
Strain variation in susceptibility to monoclonal **antibody**-induced transplantation tolerance
Davies J D; Cobbold S P; Waldmann H
Dep. Immunol., IMM-23, Scripps Res. Inst., 10550 North Torey Pines Road, La Jolla, CA 92037, USA
Transplantation (Baltimore) 63 (11). 1997. 1570-1573.
Full Journal Title: Transplantation (Baltimore)
ISSN: 0041-1337

Language: ENGLISH
Print Number: Biological Abstracts Vol. 104 Iss. 004 Ref. 053250

2/3/4 (Item 4 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

13627855 BIOSIS Number: 99627855
The immunological and pharmacodynamic effects of a humanised **non-depleting** anti-**CD4** monoclonal **antibody** (mAb) in rheumatoid arthritis (RA)
Choy E H S; Connolly D J A; Regan T; Manna V K; Rapson N; Kingsley G H; Panayi G S; Johnston J M
Glaxo Wellcome, Beckenham, London, UK
British Journal of Rheumatology 36 (SUPPL. 1). 1997. 185.
Full Journal Title: XIVth Annual General Meeting of the British Society of Rheumatology, Harrogate, England, UK, April 23-25, 1997. British Journal of Rheumatology
ISSN: 0263-7103
Language: ENGLISH
Document Type: CONFERENCE PAPER
Print Number: Biological Abstracts/RRM Vol. 049 Iss. 008 Ref. 134420

2/3/5 (Item 5 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

13627731 BIOSIS Number: 99627731
The clinical effect of a by humanised **non-depleting** anti-**CD4** monoclonal **antibody** (mAb) in rheumatoid arthritis (RA)
Panayi G S; Chov E H S; Connolly D J A; Manna V K; Regan T; Rapson N; Kingsley G H; Johnston J M
Rheumatology Unit, Guy's Hosp., UMDS, London, UK
British Journal of Rheumatology 36 (SUPPL. 1). 1997. 122.
Full Journal Title: XIVth Annual General Meeting of the British Society of Rheumatology, Harrogate, England, UK, April 23-25, 1997. British Journal of Rheumatology
ISSN: 0263-7103
Language: ENGLISH
Document Type: CONFERENCE PAPER
Print Number: Biological Abstracts/RRM Vol. 049 Iss. 008 Ref. 134296

2/3/6 (Item 6 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

13475763 BIOSIS Number: 99475763
Protection from experimental autoimmune encephalomyelitis (EAE): **Non-depleting** anti-**CD4** mAb treatment induces peripheral T-cell tolerance to MBP in PL-J mice
Biasi G; Facchinetti A; Monastra G; Mezzalira S; Sivieri S; Tavolato B; Gallo P
Inst. Exp. Pathol., Univ. Ancona, Ancona, Italy
Journal of Neuroimmunology 73 (1-2). 1997. 117-123.
Full Journal Title: Journal of Neuroimmunology
ISSN: 0165-5728
Language: ENGLISH
Print Number: Biological Abstracts Vol. 103 Iss. 009 Ref. 131432

2/3/7 (Item 7 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

13436879 BIOSIS Number: 99436879
Efficacy of RIB 5-2, a novel **non-depleting** anti-**CD4** **antibody**, in prolonging intrapulmonary transgene expression of E1-deleted adenoviral vectors
Lei D; Nelson S; Summer W R; Shellito J E; Kolls J K
LSU, Sect. Pulmonary Critical Care Med., New Orleans, LA, USA
Journal of Investigative Medicine 45 (1). 1997. 59A.
Full Journal Title: American Federation for Medical Research Southern Regional Meeting, New Orleans, Louisiana, USA, February 5-7, 1997. Journal of Investigative Medicine
ISSN: 1081-5589
Language: ENGLISH
Document Type: CONFERENCE PAPER
Print Number: Biological Abstracts/RRM Vol. 049 Iss. 004 Ref. 057731

2/3/8 (Item 8 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

13417803 BIOSIS Number: 99417803
Induction of donor specific transplantation tolerance to cardiac allografts following treatment with **nondepleting** (RIB 5-2) or depleting (OX-38) anti-**CD4** mAb plus intrathymic or intravenous donor alloantigen
Arima T; Lehmann M; Flye M W
One Barnes Hosp. Plaza, Suite 5103, St. Louis, MO 63110, USA
Transplantation (Baltimore) 63 (2). 1997. 284-292.
Full Journal Title: Transplantation (Baltimore)
ISSN: 0041-1337
Language: ENGLISH
Print Number: Biological Abstracts Vol. 103 Iss. 007 Ref. 089946

2/3/9 (Item 9 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

13402315 BIOSIS Number: 99402315
T cell hypothesis in rheumatoid arthritis (RA) tested by humanised **non-depleting** anti-**CD4** monoclonal **antibody** (mAb) treatment I: Suppression of disease activity and acute phase response
Panayi G S; Choy E H S; Connolly D J A; Manna V K; Regan T; Rapson N; Kingsley G H; Johnston J M
Rheumatology Unit, Guy's Hosp., UMDS, London, UK
Immunology 89 (SUPPL. 1). 1996. 92.
Full Journal Title: Joint Congress of the British Society for Immunology and the Biochemical Society, Harrogate, England, UK, December 10-13, 1996. Immunology
ISSN: 0019-2805
Language: ENGLISH
Document Type: CONFERENCE PAPER
Print Number: Biological Abstracts/RRM Vol. 049 Iss. 003 Ref. 048954

2/3/10 (Item 10 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

13402314 BIOSIS Number: 99402314
T cell hypothesis in rheumatoid arthritis (RA) tested by humanised **non-depleting** anti-**CD4** monoclonal **antibody** (mAb) treatment II: Clinical activity is related to pharmacodynamic effects

Choy E H S; Connolly D J A; Regan T; Manna V K; Rapson N; Kingsley G H; Panayi G S; Johnston J M
Rheumatology Unit, Guy's Hosp., UMDS, London, UK
Immunology 89 (SUPPL. 1). 1996. 92.
Full Journal Title: Joint Congress of the British Society for Immunology and the Biochemical Society, Harrogate, England, UK, December 10-13, 1996. Immunology
ISSN: 0019-2805
Language: ENGLISH
Document Type: CONFERENCE PAPER
Print Number: Biological Abstracts/RRM Vol. 049 Iss. 003 Ref. 048953

2/3/11 (Item 11 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

13319410 BIOSIS Number: 99319410
Induction of "infectious " tolerance to MHC-incompatible cardiac allografts in sensitized rat recipients treated with a **nondepleting CD4** monoclonal **antibody**
Onodera K; Lehmann M; Volk H-D; Sayegh M H; Kupiec-Weglinski J W
Surg. Res. Lab., Harv. Med. Sch., Dep. Surg. Med., Brigham and Women's Hosp., Boston, MA, USA
Surgical Forum 47 (0). 1996. 423-427.
Full Journal Title: Surgical Forum
ISSN: 0071-8041
Language: ENGLISH
Print Number: Biological Abstracts Vol. 103 Iss. 002 Ref. 022524

2/3/12 (Item 12 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

13224264 BIOSIS Number: 99224264
T cell hypothesis in rheumatoid arthritis (RA) tested by humanized **non-depleting** anti-**CD4** monoclonal **antibody** (mAb) treatment III: Immunological effects
Connolly D J A; Choy E H S; Rapson N; Regan T; Kingsley G H; Johnston J M ; Panayi G S
Rheumatol. Unit, Guy's Hosp., UMDS, London, UK
Arthritis & Rheumatism 39 (9 SUPPL.). 1996. S245.
Full Journal Title: 60th National Scientific Meeting of the American College of Rheumatology and the 31st National Scientific Meeting of the Association of Rheumatology Health Professionals, Orlando, Florida, USA, October 18-22, 1996. Arthritis & Rheumatism
ISSN: 0004-3591
Language: ENGLISH
Document Type: CONFERENCE PAPER
Print Number: Biological Abstracts/RRM Vol. 048 Iss. 011 Ref. 203385

2/3/13 (Item 13 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

13224263 BIOSIS Number: 99224263
T cell hypothesis in rheumatoid arthritis (RA) tested by humanized **non-depleting** anti-**CD4** monoclonal **antibody** (mAb) treatment II: Clinical activity is related to pharmacodynamic effects
Choy E H S; Connolly D J A; Regan T; Manna V K; Rapson N; Kingsley G H; Panayi G S; Johnston J M
Rheumatol. Unit, Guy's Hosp., UMDS, London, UK
Arthritis & Rheumatism 39 (9 SUPPL.). 1996. S244.

Full Journal Title: 60th National Scientific Meeting of the American College of Rheumatology and the 31st National Scientific Meeting of the Association of Rheumatology Health Professionals, Orlando, Florida, USA, October 18-22, 1996. Arthritis & Rheumatism
ISSN: 0004-3591
Language: ENGLISH
Document Type: CONFERENCE PAPER
Print Number: Biological Abstracts/RRM Vol. 048 Iss. 011 Ref. 203384

2/3/14 (Item 14 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

13224262 BIOSIS Number: 99224262
T cell hypothesis in rheumatoid arthritis (RA) tested by humanized **non-depleting** anti-**CD4** monoclonal **antibody** (mAb) treatment I: Suppression of disease activity and acute phase response
Panayi G S; Choy E H S; Connolly D J A; Regan T; Manna V K; Rapson N; Kingsley G H; Johnston J M
Rheumatol. Unit, Guy's Hosp., UMDS, London, UK
Arthritis & Rheumatism 39 (9 SUPPL.). 1996. S244.
Full Journal Title: 60th National Scientific Meeting of the American College of Rheumatology and the 31st National Scientific Meeting of the Association of Rheumatology Health Professionals, Orlando, Florida, USA, October 18-22, 1996. Arthritis & Rheumatism
ISSN: 0004-3591
Language: ENGLISH
Document Type: CONFERENCE PAPER
Print Number: Biological Abstracts/RRM Vol. 048 Iss. 011 Ref. 203383

2/3/15 (Item 15 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

13223537 BIOSIS Number: 99223537
Results of a placebo-controlled multicenter trial using a primatized **non-depleting**, anti-**CD4** monoclonal **antibody** in the treatment of rheumatoid arthritis
Levy R; Weisman M; Wisenhutter C; Yocum D; Schnitzer T; Goldman A; Schiff M; Leiden B F; Solinger A; MacDonald B; Lipani J
Olympia, WA 98502, USA
Arthritis & Rheumatism 39 (9 SUPPL.). 1996. S122.
Full Journal Title: 60th National Scientific Meeting of the American College of Rheumatology and the 31st National Scientific Meeting of the Association of Rheumatology Health Professionals, Orlando, Florida, USA, October 18-22, 1996. Arthritis & Rheumatism
ISSN: 0004-3591
Language: ENGLISH
Document Type: CONFERENCE PAPER
Print Number: Biological Abstracts/RRM Vol. 048 Iss. 011 Ref. 202658

2/3/16 (Item 16 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

13104687 BIOSIS Number: 99104687
Influence of selective T-lymphocyte depletion on the lung pathology of gnotobiotic calves and the distribution of different T-lymphocyte subsets following challenge with bovine respiratory syncytial virus
Thomas L H; Cook R S; Howard C J; Gaddum R M; Taylor G
Inst. Anim. Health, Compton, Newbury RH20 7NN, UK
Research in Veterinary Science 61 (1). 1996. 38-44.

Full Journal Title: Research in Veterinary Science
ISSN: 0034-5288
Language: ENGLISH
Print Number: Biological Abstracts Vol. 102 Iss. 005 Ref. 070136

2/3/17 (Item 17 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

13098437 BIOSIS Number: 99098437
CD4+ T cell mediated destruction of xenografts within cell-impermeable membranes in the absence of **CD8**+ T cells and B cells
Loudovaris T; Mandel T E; Charlton B
Baxter Healthcare Corporation, Gene Therapy Unit, Baxter Technol. Park WG2 2S, Round Lake, IL 60073-0490, USA
Transplantation (Baltimore) 61 (12). 1996. 1678-1684.
Full Journal Title: Transplantation (Baltimore)
ISSN: 0041-1337
Language: ENGLISH
Print Number: Biological Abstracts Vol. 102 Iss. 005 Ref. 063886

2/3/18 (Item 18 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

13088015 BIOSIS Number: 99088015
Kinetics of induction of transplantation tolerance with a **nondepleting** anti-**Cd4** monoclonal **antibody** and donor-specific transfusion before transplantation
Saitovitch D; Bushell A; Mabbs D W; Morris P J; Wood K J
Nuffield Dep. Surg., Univ. Oxford, John Radcliffe Hosp., Headington, Oxford OX3 9DU, UK
Transplantation (Baltimore) 61 (11). 1996. 1642-1647.
Full Journal Title: Transplantation (Baltimore)
ISSN: 0041-1337
Language: ENGLISH
Print Number: Biological Abstracts Vol. 102 Iss. 004 Ref. 053464

2/3/19 (Item 19 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

13074445 BIOSIS Number: 99074445
Prevention of collagen-induced arthritis by a **non-depleting** anti-**CD4 antibody**
Chu C Q; Londei M
Kennedy Inst. Rheumatology, London W6 7DW, UK
British Journal of Rheumatology 35 (ABSTR. SUPPL. 1). 1996. 108.
Full Journal Title: XIIIth Annual General Meeting British Society for Rheumatology, Brighton, England, UK, May 8-10, 1996. British Journal of Rheumatology
ISSN: 0263-7103
Language: ENGLISH
Document Type: CONFERENCE PAPER
Print Number: Biological Abstracts/RRM Vol. 048 Iss. 008 Ref. 139625

2/3/20 (Item 20 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

13031632 BIOSIS Number: 99031632

Immunological markers of response in a multi-dose protocol 7002 using an immunomodulating, **non-depleting** Primatized anti-**CD4** monoclonal **antibody** in rheumatoid arthritis (RA)
Solinger A; Paxton H; Wey K; Yocum D
IDEC Pharmaceuticals, San Diego, CA 92121, USA
FASEB Journal 10 (6). 1996. A1314.
Full Journal Title: Joint Meeting of the American Society for Biochemistry and Molecular Biology, the American Society for Investigative Pathology and the American Association of Immunologists, New Orleans, Louisiana, USA, June 2-6, 1996. FASEB Journal
ISSN: 0892-6638
Language: ENGLISH
Document Type: CONFERENCE PAPER
Print Number: Biological Abstracts/RRM Vol. 048 Iss. 007 Ref. 125368

2/3/21 (Item 21 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

12176618 BIOSIS Number: 98776618
The effects of **nondepleting CD4** targeted therapy in presensitized rat recipients of cardiac allografts
Binder J; Lehmann M; Graser E; Hancock W W; Watschinger B; Onodera K; Sayegh M H; Volk H-D; Kupiec-Weglinski J W
Surgical Res. Lab., Harvard Medical School, 260 Longwood Ave., Boston, MA 02115, USA
Transplantation (Baltimore) 61 (5). 1996. 804-811.
Full Journal Title: Transplantation (Baltimore)
ISSN: 0041-1337
Language: ENGLISH
Print Number: Biological Abstracts Vol. 101 Iss. 010 Ref. 143810

2/3/22 (Item 22 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

12165809 BIOSIS Number: 98765809
Immunological markers of response in a multi-dose protocol 7002 using an immunomodulating, **non-depleting** primatized-TM anti-**CD4** monoclonal **antibody** in rheumatoid arthritis (RA)
Solinger A; Paxton H; Wey K; Yocum D
IDEC Pharmaceuticals, San Diego, CA 92121, USA
FASEB Journal 10 (3). 1996. A442.
Full Journal Title: Experimental Biology 96, Part II, Washington, D.C., USA, April 14-17, 1996. FASEB Journal
ISSN: 0892-6638
Language: ENGLISH
Document Type: CONFERENCE PAPER
Print Number: Biological Abstracts/RRM Vol. 048 Iss. 005 Ref. 082598

2/3/23 (Item 23 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

11935571 BIOSIS Number: 98535571
Modulation of mitogen and recall antigen proliferation by a **non-depleting**, anti-**CD4** monoclonal **antibody**: Results of a multi-dose study
Yocum D E; Mararescu M; Soundararaian D; Nordensson K; Solinger A M; Lipani J
Univ. Ariz., Tucson, AZ 85724, USA
Arthritis & Rheumatism 38 (9 SUPPL.). 1995. S280.

Full Journal Title: 59th National Scientific Meeting of the American College of Rheumatology and the 30th National Scientific Meeting of the Association of Rheumatology Health Professionals, San Francisco, California, USA, October 21-26, 1995. Arthritis & Rheumatism
ISSN: 0004-3591
Language: ENGLISH
Document Type: CONFERENCE PAPER
Print Number: Biological Abstracts/RRM Vol. 047 Iss. 012 Ref. 205446

2/3/24 (Item 24 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

11935007 BIOSIS Number: 98535007
Treating rheumatoid arthritis with a **non-depleting** anti-**CD4** monoclonal **antibody** (MAb)
Moreland L W; Bucy R P; Knowles R W; Wacholtz M C; Haverty T P; Koopman W J
Univ. Alabama at Birmingham, Birmingham, AL, USA
Arthritis & Rheumatism 38 (9 SUPPL.). 1995. S186.
Full Journal Title: 59th National Scientific Meeting of the American College of Rheumatology and the 30th National Scientific Meeting of the Association of Rheumatology Health Professionals, San Francisco, California, USA, October 21-26, 1995. Arthritis & Rheumatism
ISSN: 0004-3591
Language: ENGLISH
Document Type: CONFERENCE PAPER
Print Number: Biological Abstracts/RRM Vol. 047 Iss. 012 Ref. 204882

2/3/25 (Item 25 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

11935003 BIOSIS Number: 98535003
Results of a multi-dose protocol 7002 using an immunomodulating, **non-depleting** PRIMATIZED anti-**cD4** monoclonal **antibody** in rheumatoid arthritis (RA)
Kaine J; Solinger A; Yocum D; Lipani J; Klas P; Tesser J; Wiesenhutter C; O'Sullivan F; Shuman S; Rigby W
Sarasota Arthritis Center, Sarasota, FL 34239, USA
Arthritis & Rheumatism 38 (9 SUPPL.). 1995. S185.
Full Journal Title: 59th National Scientific Meeting of the American College of Rheumatology and the 30th National Scientific Meeting of the Association of Rheumatology Health Professionals, San Francisco, California, USA, October 21-26, 1995. Arthritis & Rheumatism
ISSN: 0004-3591
Language: ENGLISH
Document Type: CONFERENCE PAPER
Print Number: Biological Abstracts/RRM Vol. 047 Iss. 012 Ref. 204878

2/3/26 (Item 26 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

11922333 BIOSIS Number: 98522333
Administration of a **nondepleting** Anti-**CD4** monoclonal **antibody** (W3-25) prevents adjuvant arthritis, even upon rechallenge: Parallel administration of a depleting anti-**CD8** monoclonal **antibody** (OX8) does not modify the effect of W3-25
Pelegri C; Morante M P; Castellote C; Castell M; Franch A
Unit Physiol., Fac. Pharm., Univ. Barcelona, Barcelona, Spain
Cellular Immunology 165 (2). 1995. 177-182.

Full Journal Title: Cellular Immunology
ISSN: 0008-8749
Language: ENGLISH
Print Number: Biological Abstracts Vol. 100 Iss. 011 Ref. 173190

2/3/27 (Item 27 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

11922318 BIOSIS Number: 98522318
Therapeutic monoclonal **antibodies**
Choy E H S; Panayi G S; Kingsley G H
Rheumatol. Unit, Div. Medicine, UMDS, 4th Floor, Hunt's House, Guy's Hospital, St. Thomas Street, London SE1 9RT, UK
British Journal of Rheumatology 34 (8). 1995. 707-715.
Full Journal Title: British Journal of Rheumatology
ISSN: 0263-7103
Language: ENGLISH
Print Number: Biological Abstracts Vol. 100 Iss. 011 Ref. 173175

2/3/28 (Item 28 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

11916953 BIOSIS Number: 98516953
Transplantation tolerance induced by antigen pretreatment and depleting anti-**CD4 antibody** depends on **CD4**+ T cell regulation during the induction phase of the response
Bushell A; Morris P J; Wood K J
Nuffield Dep. Surgery, Univ. Oxford, John Radcliffe Hospital, Headington, Oxford OX3 9DU, UK
European Journal of Immunology 25 (9). 1995. 2642-2649.
Full Journal Title: European Journal of Immunology
ISSN: 0014-2980
Language: ENGLISH
Print Number: Biological Abstracts Vol. 100 Iss. 011 Ref. 167810

2/3/29 (Item 29 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

11809407 BIOSIS Number: 98409407
Early-appearing tumour-infiltrating natural killer cells play a crucial role in the generation of anti-tumor T lymphocytes
Kurosawa S; Harada M; Matsuzaki G; Shinomiya Y; Terao H; Kobayashi N; Nomoto K
Dep. Virology, Med. Inst. Bioregulation, Kyushu Univ., 3-1-1 Maidashi Higashi-ku, Fukuoka 812, Japan
Immunology 85 (2). 1995. 338-346.
Full Journal Title: Immunology
ISSN: 0019-2805
Language: ENGLISH
Print Number: Biological Abstracts Vol. 100 Iss. 006 Ref. 086999

2/3/30 (Item 30 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

11807249 BIOSIS Number: 98407249
Regulation of nitric oxide release by macrophages after intratracheal lipopolysaccharide

Shellito J E; Kolls J K; Summer W R
Sect. Pulmonary Critical Care Med., Louisiana State Univ. Med. Cent., Suite 3205, 1901 Perdido St., New Orleans, LA 70112, USA
American Journal of Respiratory Cell and Molecular Biology 13 (1). 1995. 45-53.
Full Journal Title: American Journal of Respiratory Cell and Molecular Biology
ISSN: 1044-1549
Language: ENGLISH
Print Number: Biological Abstracts Vol. 100 Iss. 006 Ref. 084841

2/3/31 (Item 31 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

11760328 BIOSIS Number: 98360328
Activation of **CD4**+ T cells in the presence of a **nondepleting** monoclonal **antibody** to **CD4** induces a Th2-Type response in vitro
Stumbles P; Mason D
MRC Cellular Immunol. Unit, Sir William Dunn Sch. Pathol., University Oxford, South Parks Rd., Oxford OX1 3RE, UK
Journal of Experimental Medicine 182 (1). 1995. 5-13.
Full Journal Title: Journal of Experimental Medicine
ISSN: 0022-1007
Language: ENGLISH
Print Number: Biological Abstracts Vol. 100 Iss. 004 Ref. 052166

2/3/32 (Item 32 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

11612318 BIOSIS Number: 98212318
Induction of transplantation tolerance using a **nondepleting** anti-**CD4** MAb and donor-specific transfusion before transplantation: Evidence that a critical period of time is required for the development of immunological unresponsiveness
Saitovitch D; Bushell A R; Morris P J; Wood K J
Nuffield Dep. Surg., John Radcliffe Hosp., Headington, Oxford OX3 9DU, UK
Transplantation Proceedings 27 (1). 1995. 117-118.
Full Journal Title: XVth World Congress of the Transplantation Society, Kyoto, Japan, August 28-September 2, 1994. Transplantation Proceedings
ISSN: 0041-1345
Language: ENGLISH
Document Type: CONFERENCE PAPER
Print Number: Biological Abstracts/RRM Vol. 047 Iss. 005 Ref. 085981

2/3/33 (Item 33 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

11612317 BIOSIS Number: 98212317
Donor-specific transplantation unresponsiveness in sensitized rats following treatment with a **nondepleting** anti-**CD4** MAb is associated with selective intragraft sparing of TH2-like cells
Binder J; Hancock W W; Wasowska B; Gallon L; Watschinger B; Sayegh M H; Brock J; Lehmann M; Volk H D; Kupiec-Weglinski J W
Surg. Res. Lab., Harv. Med. Sch., 260 Longwood Ave., Boston, MA 02115, USA
Transplantation Proceedings 27 (1). 1995. 114-116.
Full Journal Title: XVth World Congress of the Transplantation Society, Kyoto, Japan, August 28-September 2, 1994. Transplantation Proceedings
ISSN: 0041-1345

Language: ENGLISH
Document Type: CONFERENCE PAPER
Print Number: Biological Abstracts/RRM Vol. 047 Iss. 005 Ref. 085980

2/3/34 (Item 34 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

11435757 BIOSIS Number: 98035757
Donor-specific transplantation unresponsiveness in sensitized rats following treatment with a **nondepleting** anti-**CD4** monoclonal **antibody**
Binder J; Sayegh M H; Watschinger B; Hancock W W; Lehmann M; Volk H D; Kupiec-Weglinski J W
Surg. Res. Lab., Harv. Med. Sch., Dep. Surg. Med., Brigham and Women's Hosp., Boston, MA, USA
Surgical Forum 45 (0). 1994. 438-442.
Full Journal Title: Surgical Forum
ISSN: 0071-8041
Language: ENGLISH
Print Number: Biological Abstracts Vol. 099 Iss. 002 Ref. 020301

2/3/35 (Item 35 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

11345675 BIOSIS Number: 97545675
Mechanisms in **CD4 antibody**-mediated transplantation tolerance: Kinetics of induction, antigen dependency and role of regulatory T cells
Scully R; Qin S; Cobbold S; Waldmann H
Sir William Dunn Sch. Pathol., South Parks Road, Oxford OX1 3RE, UK
European Journal of Immunology 24 (10). 1994. 2383-2392.
Full Journal Title: European Journal of Immunology
ISSN: 0014-2980
Language: ENGLISH
Print Number: Biological Abstracts Vol. 098 Iss. 012 Ref. 163298

2/3/36 (Item 36 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

11345669 BIOSIS Number: 97545669
Immunological approach to inhibit formation of anti-**antibodies** to allo- and xenogeneic anti-T cell immunoglobulin
Mysliwietz J; Thierfelder S; Mocikat R; Kremmer E
GSF, Inst. Immunol., Marchioninistr. 25, D-81377 Muenchen, GER
European Journal of Immunology 24 (10). 1994. 2323-2328.
Full Journal Title: European Journal of Immunology
ISSN: 0014-2980
Language: ENGLISH
Print Number: Biological Abstracts Vol. 098 Iss. 012 Ref. 163292

2/3/37 (Item 37 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

11220223 BIOSIS Number: 97420223
Sparing of the ipsilateral retina after anterior chamber inoculation of HSV-1: Requirement for either **CD4**+ or **CD8**+ T cells
Azumi A; Atherton S S

Dep. Cellular and Structural Biol., Univ. Tex. Health Sci. Cent. San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78284-7762, USA
Investigative Ophthalmology & Visual Science 35 (8). 1994. 3251-3259.
Full Journal Title: Investigative Ophthalmology & Visual Science
ISSN: 0146-0404
Language: ENGLISH
Print Number: Biological Abstracts Vol. 098 Iss. 007 Ref. 091035

2/3/38 (Item 38 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

11130425 BIOSIS Number: 97330425
The role of **CD4**+ and **CD8**+ cell subsets in the growth-control of MCH-13 fibrosarcoma
Lucin K; Culo F; Jonjic N
Dep. Pathol., Pathol. Anatomy, Med. Fac., University Rijeka, Olge Ban 22, 51000 Rijeka, CRO
Periodicum Biologorum 95 (4). 1993. 395-400.
Full Journal Title: Periodicum Biologorum
ISSN: 0031-5362
Language: ENGLISH
Print Number: Biological Abstracts Vol. 098 Iss. 003 Ref. 036937

2/3/39 (Item 39 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

11122665 BIOSIS Number: 97322665
Nondepleting anti-**CD4 antibodies** in transplantation: Evidence that modulation is far less effective than prolonged **CD4** blockade
Darby C R; Bushell A; Morris P J; Wood K J
Nuffield Dep. Surg., Univ. Oxford, John Radcliffe Hosp., Oxford OX3 9DU, UK
Transplantation (Baltimore) 57 (10). 1994. 1419-1426.
Full Journal Title: Transplantation (Baltimore)
ISSN: 0041-1337
Language: ENGLISH
Print Number: Biological Abstracts Vol. 098 Iss. 003 Ref. 029177

2/3/40 (Item 40 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

11114409 BIOSIS Number: 97314409
Production of erythrocyte autoantibodies in NZB mice is inhibited by **CD4 antibodies**
Oliveira G G S; Hutchinggs P R; Roitt I M; Lydyard P M
Dep. Immunol., Univ. Coll. London Med. Sch., Arthur Stanley House, 40-50 Tottenham St., London W1P 9PG, UK
Clinical and Experimental Immunology 96 (2). 1994. 297-302.
Full Journal Title: Clinical and Experimental Immunology
ISSN: 0009-9104
Language: ENGLISH
Print Number: Biological Abstracts Vol. 098 Iss. 002 Ref. 020921

2/3/41 (Item 41 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

10974934 BIOSIS Number: 97174934
Modulation of murine herpes simplex virus type 1 retinitis in the uninoculated eye by **CD4**+ T lymphocytes
Azumi A; Cousins S W; Kanter M Y; Atherton S S
Dep. Cell. Structural Biol., Univ. Texas Health Sci. Cent. San Antonio, 7703 Floyd Curl Dr., San Antonio, TX 78284-7762, USA
Investigative Ophthalmology & Visual Science 35 (1). 1994. 54-63.
Full Journal Title: Investigative Ophthalmology & Visual Science
ISSN: 0146-0404
Language: ENGLISH
Print Number: Biological Abstracts Vol. 097 Iss. 008 Ref. 108605

2/3/42 (Item 42 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

10973679 BIOSIS Number: 97173679
A **nondepleting** anti-rat **CD4** monoclonal **antibody** that suppresses T helper 1-like but not T helper 2-like intragraft lymphokine secretion induces long-term survival of renal allografts
Siegling A; Lehmann M; Riedel H; Platzer C; Brock J; Emmrich F; Volk H-D
Inst. Med. Immunologie, Med. Fakultat, Schummanstr. 20/21, D-O-1040 Berlin, GER
Transplantation (Baltimore) 57 (3). 1994. 464-467.
Full Journal Title: Transplantation (Baltimore)
ISSN: 0041-1337
Language: ENGLISH
Print Number: Biological Abstracts Vol. 097 Iss. 008 Ref. 107344

2/3/43 (Item 43 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

10845914 BIOSIS Number: 97045914
Comparison of **CD4** depleting and **nondepleting** monoclonal **antibodies** in the mouse heart allograft model
Han W R; Mottram P L; McKenzie I F C
Dep. Surgery, Royalf Melbourne Hosp., Parville 3050, AUL
Transplantation Proceedings 25 (5). 1993. 2933-2934.
Full Journal Title: Transplantation Proceedings
ISSN: 0041-1345
Language: ENGLISH
Print Number: Biological Abstracts Vol. 097 Iss. 003 Ref. 029799

2/3/44 (Item 44 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

10832905 BIOSIS Number: 97032905
Tolerance to IDDM induced by **CD4 antibodies** in nonobese diabetic mice is reversed by cyclophosphamide
Parish N M; Hutchings P R; Waldmann H; Cooke A
Div. Immunol., Dep. Pathol., Univ. Cambridge, Tennis Court Rd., Cambridge CB2 1QP, UK
Diabetes 42 (11). 1993. 1601-1605.
Full Journal Title: Diabetes
ISSN: 0012-1797
Language: ENGLISH

2/3/45 (Item 45 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

(c) 1997 BIOSIS. All rts. reserv.

10805769 BIOSIS Number: 97005769
T-cell recognition of a cross-reactive antigen(s) in erythrocytic stages of Plasmodium falciparum and Plasmodium yoelii: Inhibition of parasitemia by this antigen(s)
Lucas B; Engels A; Camus D; Haque A
Centre Immunol., Biol. Parasitaire, Inst. Pasteur, 59019 Lille, FRA
Infection and Immunity 61 (11). 1993. 4863-4869.
Full Journal Title: Infection and Immunity
ISSN: 0019-9567
Language: ENGLISH
Print Number: Biological Abstracts Vol. 097 Iss. 001 Ref. 005267

2/3/46 (Item 46 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1997 BIOSIS. All rts. reserv.

10479491 BIOSIS Number: 96079491
CONTROL OF IMMUNE-MEDIATED DISEASE OF THE CENTRAL NERVOUS SYSTEM WITH MONOCLONAL **CD4**-SPECIFIC **ANTIBODIES**
O'NEILL J K; BAKER D; DAVISON A N; ALLEN S J; BUTTER C; WALDMANN H; TURK J L
DEP. PATHOLOGY, ROYAL COLL. SURGEONS ENGLAND, 35-43 LINCOLN'S INN FIELDS, LONDON WC2A 3PN, UK.
J NEUROIMMUNOL 45 (1-2). 1993. 1-14. CODEN: JNRID
Full Journal Title: Journal of Neuroimmunology
Language: ENGLISH

2/3/47 (Item 47 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1997 BIOSIS. All rts. reserv.

10131551 BIOSIS Number: 95131551
ACTIVE SUPPRESSION INDUCED BY ANTI-**CD4**
HUTCHINGS P R; COOKE A; DAWE K; WALDMANN H; ROITT I M
PATHOL. DEP., UNIV. CAMBRIDGE, TENNIS COURT ROAD, CAMBRIDGE CB2 1QP, UK.
EUR J IMMUNOL 23 (4). 1993. 965-968. CODEN: EJIMA
Full Journal Title: European Journal of Immunology
Language: ENGLISH

2/3/48 (Item 48 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1997 BIOSIS. All rts. reserv.

10017021 BIOSIS Number: 95017021
DEVELOPMENT OF MURINE LUPUS IN **CD4**-DEPLETED NZB-NZW MICE SUSTAINED INHIBITION OF RESIDUAL **CD4**-POSITIVE T CELLS IS REQUIRED TO SUPPRESS AUTOIMMUNITY
CONNOLLY K; ROUBINIAN J R; WOFSY D
ARTHRITIS/IMMUNOL. SECTION, VETRANS ADM. MED. CENT., 4150 CLEMENT STREET, SAN FRANCISCO, CALIF. 94121.
J IMMUNOL 149 (9). 1992. 3083-3088. CODEN: JOIMA
Full Journal Title: Journal of Immunology
Language: ENGLISH

2/3/49 (Item 49 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1997 BIOSIS. All rts. reserv.

9629018 BIOSIS Number: 94134018

DOWN REGULATION OF STEM CELL COLONY FORMATION BY PURIFIED **CD8** LYMPHOCYTES AND **CD8** CONDITIONED MEDIUM POTENTIAL IMPORTANCE FOR BONE MARROW TRANSPLANTATION IN LEUKEMIA
GAZITT Y; HE Y-J
PEDIATR. HEMATOL./ONCOL., BOX 100296 JHMHC, GAINESVILLE, FLA. 32610-0296, USA.
LEUK LYMPHOMA 8 (1-2). 1992. 117-127. CODEN: LELYE
Language: ENGLISH

2/3/50 (Item 50 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

9627323 BIOSIS Number: 94132323
EVIDENCE THAT LONG-TERM CARDIAC ALLOGRAFT SURVIVAL INDUCED BY ANTI-**CD4** MONOCLONAL **ANTIBODY** DOES NOT REQUIRE DEPLETION OF **CD4** -POSITIVE T CELLS
DARBY C R; MORRIS P J; WOOD K J
NUFFIELD DEP. SURGERY, JOHN RADCLIFFE HOSPITAL, HEADINGTON, OXFORD OX3 9DU, U.K.
TRANSPLANTATION (BALTIMORE) 54 (3). 1992. 483-490. CODEN: TRPLA
Full Journal Title: TRANSPLANTATION (Baltimore)
Language: ENGLISH

2/3/51 (Item 51 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

9568863 BIOSIS Number: 94073863
THE USE OF A **NON-DEPLETING** ANTI-**CD4** MONOCLONAL **ANTIBODY** TO RE-ESTABLISH TOLERANCE TO BETA CELLS IN NOD MICE
HUTCHINGS P; O'REILLY L; PARISH N M; WALDMANN H; COOKE A
DEP. PATHOL., UNIV. CAMBRIDGE, TENNIS COURT RD., CAMBRIDGE CB2 1QP, GB.
EUR J IMMUNOL 22 (7). 1992. 1913-1918. CODEN: EJIMA
Full Journal Title: European Journal of Immunology
Language: ENGLISH

2/3/52 (Item 52 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

9115339 BIOSIS Number: 93100339
COMPARISON OF GK1.5 AND CHIMERIC RAT-MOUSE GK1.5 ANTI-**CD4** **ANTIBODIES** FOR PROLONGATION OF SKIN ALLOGRAFT SURVIVAL AND SUPPRESSION OF ALLOANTIBODY PRODUCTION IN MICE
RASHID A; AUCHINCLOSS H JR; SHARON J
BOSTON UNIV. SCH. MED., 80 EAST CONCORD STREET, K707, BOSTON, MASS. 02118.
J IMMUNOL 148 (5). 1992. 1382-1388. CODEN: JOIMA
Full Journal Title: Journal of Immunology
Language: ENGLISH

2/3/53 (Item 53 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

9032472 BIOSIS Number: 93017472
ANTI-CD2 **ANTIBODIES** INDUCE T CELL UNRESPONSIVENESS IN-VIVO
GUECKEL B; BEREK C; LUTZ M; ALTEVOGT P; SCHIRRMACHER V; KYEWSKI B A
INST. IMMUNOL. AND GENETICS, GERMAN CANCER RES. CENT., IM NEUENHEIMER FELD 280, D-6900 HEIDELBERG, GER.

J EXP MED 174 (5). 1991. 957-968. CODEN: JEMEA
Full Journal Title: Journal of Experimental Medicine
Language: ENGLISH

2/3/54 (Item 54 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

9020424 BIOSIS Number: 93005424
SUPPRESSION IN MURINE EXPERIMENTAL AUTOIMMUNE THYROIDITIS IN-VIVO INHIBITION OF **CD4**-POSITIVE T CELL-MEDIATED RESISTANCE BY A **NONDEPLETING** RAT **CD4** MONOCLONAL **ANTIBODY**
NABOZNY G H; COBBOLD S P; WALDMANN H; KONG Y-C M
DEP. IMMUNOL. MICROBIOL, WAYNE STATE UNIV. SCH. MED., DETROIT, MICH.
CELL IMMUNOL 138 (1). 1991. 185-196. CODEN: CLIMB
Full Journal Title: Cellular Immunology
Language: ENGLISH

2/3/55 (Item 55 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

8167526 BIOSIS Number: 91088526
THE INDUCTION OF SKIN GRAFT TOLERANCE IN MAJOR HISTOCOMPATIBILITY COMPLEX-MISMATCHED OR PRIMED RECIPIENTS PRIMED T CELLS CAN BE TOLERIZED IN THE PERIPHERY WITH ANTI-**CD4** AND ANTI-**CD8 ANTIBODIES**
COBBOLD S P; MARTIN G; WALDMANN H
DIV. IMMUNOL., CAMBRIDGE UNIV., DEP. PATHOL., LEVEL 3 LAB. BLOCK, NEW ADDENBROOKES HOSP., CAMBRIDGE CB2 2QQ, GREAT BRITIAN.
EUR J IMMUNOL 20 (12). 1990. 2747-2756. CODEN: EJIMA
Full Journal Title: European Journal of Immunology
Language: ENGLISH

2/3/56 (Item 56 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

8095291 BIOSIS Number: 91016291
RESISTANCE TO INFECTION BY HIV-1 OF PERIPHERAL BLOOD MONONUCLEAR CELLS FROM HIV-1-INFECTED PATIENTS IS PROBABLY MEDIATED BY NEUTRALIZING **ANTIBODIES**
TREMBLAY M; NUMAZAKI K; LI X; GORNITSKY M; HISCOTT J; WAINBERG M A
MCGILL AIDS CENTRE JEWISH GENERAL HOSP., 3755 COTE STE-CATHERINE ROAD, MONTREAL, QUEBEC H3T 1E2, CAN.
J IMMUNOL 145 (9). 1990. 2896-2901. CODEN: JOIMA
Full Journal Title: Journal of Immunology
Language: ENGLISH

2/3/57 (Item 57 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

7529494 BIOSIS Number: 39042101
A **NONDEPLETING** RAT **CD4** MONOCLONAL **ANTIBODY** MAB INHIBITS **CD4**-POSITIVE SUPPRESSOR-MEDIATED RESISTANCE TO MURINE EXPERIMENTAL AUTO-IMMUNE THYROIDITIS EAT IN-VIVO
NABOZNY G H; COBBOLD S; WALDMANN H; KONG Y M
WAYNE STATE UNIV. SCH. MED., DETROIT, MICH. 48201.
JOINT MEETING OF THE AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, AND THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, NEW ORLEANS, LOUISIANA, USA, JUNE 4-7, 1990. FASEB (FED AM SOC EXP BIOL) J 4 (7). 1990.

A2099. CODEN: FAJOE
Language: ENGLISH
Document Type: CONFERENCE PAPER

2/3/58 (Item 58 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

7185784 BIOSIS Number: 88108529
ENGAGEMENT OF CD-4 AND CD-8 ACCESSORY MOLECULES IS REQUIRED FOR T CELL MATURATION
RAMSDELL F; FOWLKES B J
LAB. CELLULAR MOLECULAR IMMUNOL., NIAID, NIH, BUILDING 4, ROOM 111, BETHESDA, MD 20892.
J IMMUNOL 143 (5). 1989. 1467-1471. CODEN: JOIMA
Full Journal Title: Journal of Immunology
Language: ENGLISH

2/3/59 (Item 59 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

7104252 BIOSIS Number: 88026997
AN INCREASE IN THE SURVIVAL OF MURINE H-2-MISMATCHED CULTURED FETAL PANCREAS ALLOGRAFTS USING DEPLETING OR **NONDEPLETING** ANTI-**CD4** MONOCLONAL **ANTIBODIES** AND A FURTHER INCREASE WITH THE ADDITION OF CYCLOSPORINE
BURKHARDT K; CHARLTON B; MANDEL T E
TRANSPANTATION UNIT, WALTER AND ELIZA HALL INST. MED. RES., POST OFFICE, ROYAL MELBOURNE HOSP., VICTORIA 3050, AUST.
TRANSPLANTATION (BALTIMORE) 47 (5). 1989. 771-775. CODEN: TRPLA
Full Journal Title: TRANSPLANTATION (Baltimore)
Language: ENGLISH

2/3/60 (Item 60 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

7083977 BIOSIS Number: 88006722
ENDOGENOUSLY GENERATED ACTIVATED KILLER CELLS CIRCULATE AFTER AUTOLOGOUS AND ALLOGENEIC MARROW TRANSPLANTATION BUT NOT AFTER CHEMOTHERAPY
REITTIE J E; GOTTLIEB D; HESLOP H E; LEGER O; DEXLER H G; HAZLEHURST G; HOFFBRAND A V; PRENTICE H G; BRENNER M K
DEP. HAEMATOL., ROYAL FREE HOSP., POND ST., LONDON, NW3, UK.
BLOOD 73 (5). 1989. 1351-1358. CODEN: BLOOA
Full Journal Title: Blood
Language: ENGLISH

2/3/61 (Item 61 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

7010730 BIOSIS Number: 87071251
ADOPTIVE IMMUNITY IN IMMUNE-DEFICIENT SCID-SCID MICE I. DIFFERENTIAL REQUIREMENTS OF NAIVE AND PRIMED LYMPHOCYTES FOR **CD4**-POSITIVE T CELLS DURING REJECTION OF MINOR HISTOCOMPATIBILITY ANTIGEN-DISPARATE SKIN GRAFTS
ROOPENIAN D C; ANDERSON P S
JACKSON LAB., BAR HARBOR, ME 04609.
TRANSPLANTATION (BALTIMORE) 46 (6). 1988. 899-904. CODEN: TRPLA
Full Journal Title: TRANSPLANTATION (Baltimore)
Language: ENGLISH

2/3/62 (Item 62 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

7010433 BIOSIS Number: 87070954
T-CELL-MEDIATED PROTECTION OF MICE AGAINST VIRULENT MYCOBACTERIUM-TUBERCULOSIS
LEVETON C; BARNASS S; CHAMPION B; LUCAS S; DE SOUZA B; NICOL M; BANERJEE D; ROOK G
DEP. MED. MICROBIOL., UNIV. COLL., LONDON W1P 7PP, U.K.
INFECT IMMUN 57 (2). 1989. 390-395. CODEN: INFIB
Full Journal Title: Infection and Immunity
Language: ENGLISH

2/3/63 (Item 63 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

6649128 BIOSIS Number: 86115679
HIGH INCIDENCE OF EARLY LEUKEMIC RELAPSE IN PATIENTS GIVEN CYCLOSPORIN AND T CELL DEPLETED HLA-IDENTICAL SIBLING MARROW TRANSPLANTS FOR ACUTE LEUKEMIA IN FIRST REMISSION
ATKINSON K; BIGGS J; DODDS A; CONCANNON A; DOWNS K; ASHBY M; MCKENZIE I F C
DEP. HAEMATOL., ST. VINCENT'S HOSP., DARLINGHURST, NSW 2010, AUSTRALIA.
AUST N Z J MED 18 (4). 1988. 587-593. CODEN: ANZJB
Full Journal Title: Australian and New Zealand Journal of Medicine
Language: ENGLISH

2/3/64 (Item 64 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

5934551 BIOSIS Number: 84067116
CD4 POSITIVE T CELLS APPEAR CAPABLE OF INITIATING GRAFT-VERSUS-HOST DISEASE ACROSS NON-MAJOR HISTOCOMPATIBILITY COMPLEX MHC BARRIERS IN MAN
ATKINSON K; COOLEY M; FARRELLY H; O'FLAHERTY E; ASHBY M; BIGGS J
DEP. HAEMATOL., ST VINCENT'S HOSP., DARLINGHURST, NSW 2010, AUSTRALIA.
BONE MARROW TRANSPLANT 2 (1). 1987. 79-84. CODEN: BMTRE
Full Journal Title: Bone Marrow Transplantation
Language: ENGLISH

2/3/65 (Item 65 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

5856041 BIOSIS Number: 83118348
A COMPARATIVE STUDY OF T-CELL DEPLETED AND **NON-DEPLETED** MARROW TRANSPLANTATION FOR HEMATOLOGICAL MALIGNANCY
ATKINSON K; ASHBY M; BIGGS J; CONCANNON A; COOLEY M; DODDS A; FARRELLY H; MORGAN G; O'FLAHERTY E; ET AL
BONE MARROW TRANSPLANT. UNIT, ST. VICENT'S HOSP., DARLINGHURST, NSW 2010.
AUST N Z J MED 17 (1). 1987. 16-23. CODEN: ANZJB
Full Journal Title: Australian and New Zealand Journal of Medicine
Language: ENGLISH

2/3/66 (Item 1 from file: 72)
DIALOG(R)File 72:EMBASE

10211048 EMBASE No: 97016020
Nondepleting anti-**CD4** **antibody** treatment prolongs lung-directed E1-deleted adenovirus-mediated gene expression in rats
Lei D.; Lehmann M.; Shellito J.E.; Nelson S.; Siegling A.; Volk H.-D.; Kolls J.K.
USA
Human Gene Therapy (USA) , 1996, 7/18 (2273-2279) CODEN: HGTHE ISSN: 1043-0342
DOCUMENT TYPE: Journal
LANGUAGES: English SUMMARY LANGUAGES: English
NUMBER OF REFERENCES: 40

2/3/67 (Item 2 from file: 72)
DIALOG(R)File 72:EMBASE

10014576 EMBASE No: 96188262
Kinetics of induction of transplantation tolerance with a **nondepleting** anti-**Cd4** monoclonal **antibody** and donor-specific transfusion before transplantation: A critical period of time is required for development of immunological unresponsiveness
Saitovitch D.; Bushell A.; Mabbs D.W.; Morris P.J.; Wood K.J.
Nuffield Department of Surgery, University of Oxford, John Radcliffe Hospital, Headington, Oxford OX3 9DU United Kingdom
Transplantation (USA) , 1996, 61/11 (1642-1647) CODEN: TRPLA ISSN: 0041-1337
LANGUAGES: English SUMMARY LANGUAGES: English

2/3/68 (Item 3 from file: 72)
DIALOG(R)File 72:EMBASE

9976377 EMBASE No: 96158019
Assessment of chronic rejection in permanent accepted renal allografts in anti-**CD4** treated rats
Risch K.; Heemann U.; Graser E.; Nebe B.; Nizze H.; Lacha J.; Brock J.; Volk H.-D.; Lehmann M.
Institut fur medizinische Biochemie, Schillingallee 70, D-18057 Rostock Germany
Clinical Nephrology (Germany) , 1996, 45/5 (358-360) CODEN: CLNHB ISSN: 0301-0430
LANGUAGES: English SUMMARY LANGUAGES: English

2/3/69 (Item 4 from file: 72)
DIALOG(R)File 72:EMBASE

9787616 EMBASE No: 95351540
T-cell regulation
Choy E.H.S.; Kingsley G.H.; Panayi G.S.
UMDS, Rheumatology Unit, Guy's Hospital, St Thomas Street, London SE1 9RT United Kingdom
Bailliere's Clinical Rheumatology (United Kingdom) , 1995, 9/4 (653-671) CODEN: BCRHE ISSN: 0950-3579
LANGUAGES: English SUMMARY LANGUAGES: English

2/3/70 (Item 5 from file: 72)
DIALOG(R)File 72:EMBASE

9532547 EMBASE No: 95106020
Anti-**CD4** monoclonal **antibody** immune intervention in patients with newly diagnosed Type I (insulin-dependent) diabetes mellitus
Hehmke B.; Kuttler B.; Laube F.; Gens E.; Michaelis D.; Hahn H.-J.; Schulze-Koops H.; Emmrich F.
Institute Diabetes 'Gerhardt Katsch', Dept Experimental Clin Endocrinology, D-17495 Karlsburg Germany
Diabetes, Nutrition and Metabolism - Clinical and Experimental (Italy) , 1994, 7/5 (273-280) CODEN: DNMEE ISSN: 0394-3402
LANGUAGES: English SUMMARY LANGUAGES: English

2/3/71 (Item 6 from file: 72)
DIALOG(R)File 72:EMBASE

9312537 EMBASE No: 94265851
Expression of type 3 complement receptor on activated **CD8**+ T cells facilitates homing to inflammatory sites
Nielsen H.V.; Christensen J.P.; Andersson E.C.; Marker O.; Thomsen A.R.
Medical Microbiol./Immunology Inst., Panum Institute, University of Copenhagen, 3c Blegdamsvej, DK-2200 N Copenhagen Denmark
J. IMMUNOL. (USA) , 1994, 153/5 (2021-2028) CODEN: JOIMA ISSN: 0022-1767
LANGUAGES: English SUMMARY LANGUAGES: English

2/3/72 (Item 7 from file: 72)
DIALOG(R)File 72:EMBASE

8677807 EMBASE No: 92358337
Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of **CD4**+ T cells
Connors M.; Kulkarni A.B.; Firestone C.-Y.; Holmes K.L.; Morse H.C. III; Sotnikov A.V.; Murphy B.R.
Respiratory Viruses Section, Laboratory of Infectious Diseases, NIAID, 9000 Rockville Pike, Bethesda, MD 20892 USA
J. VIROL. (USA) , 1992, 66/12 (7444-7451) CODEN: JOVIA ISSN: 0022-538X
LANGUAGES: English SUMMARY LANGUAGES: English

2/3/73 (Item 8 from file: 72)
DIALOG(R)File 72:EMBASE

8675097 EMBASE No: 92355607
Anti-**CD4** monoclonal **antibodies** in therapy: Creation of nonclassical tolerance in the adult
Shizuru J.A.; Alters S.E.; Fathman C.G.
Stanford Univ. School of Medicine, Div. of Rheumatology and Immunology, Stanford, CA 94305 USA
IMMUNOL. REV. (Denmark) , 1992, -/129 (105-130) CODEN: IMRED ISSN: 0105-2896 ADONIS ORDER NUMBER: 010528969200046X
LANGUAGES: English SUMMARY LANGUAGES: English

2/3/74 (Item 9 from file: 72)
DIALOG(R)File 72:EMBASE

8183556 EMBASE No: 91209639
Monoclonal **antibody** therapy for the induction of transplantation tolerance

Cobbold S.P.
Division of Immunology, Cambridge University Department of Pathology, Tennis Court Road, Cambridge CB1 2QP United Kingdom
IMMUNOL. LETT. (Netherlands) , 1991, 29/1-2 (117-122) CODEN: IMLED ISSN: 0165-2478 ADONIS ORDER NUMBER: 016524789100175N
LANGUAGES: English

2/3/75 (Item 10 from file: 72)
DIALOG(R)File 72:EMBASE

8013038 EMBASE No: 91038466
Induction of tolerance in peripheral T cells with monoclonal **antibodies**
Qin S.; Wise M.; Cobbold S.P.; Leong L.; Kong Y.-C.M.; Parnes J.R.; Waldmann H.
Division of Immunology, Department of Pathology, Cambridge University, Cambridge CB2 2QQ United Kingdom
EUR. J. IMMUNOL. (Germany, Federal Republic of) , 1990, 20/12 (2737-2745) CODEN: EJIMA ISSN: 0014-2980
LANGUAGES: English

2/3/76 (Item 1 from file: 154)
DIALOG(R)File 154:MEDLINE(R)

08981482 97119022
In vivo depletion of NKR-P1 positive cells in the recipient prior to small bowel transplantation enhances graft-versus-host disease (GvHD) in the rat.
Fandrich F; Exner B; Papachrysanthou A; Zhu X; Jahnke T; Chambers WH; Zavazava N
Department of General and Thoracic Surgery, University of Kiel, Germany.
Transpl Int (GERMANY) 1996, 9 Suppl 1 pS275-80, ISSN 0934-0874 Journal Code: ADY
Languages: ENGLISH
Document type: JOURNAL ARTICLE

2/3/77 (Item 2 from file: 154)
DIALOG(R)File 154:MEDLINE(R)

08976415 97180874
Type 2 helper T cell-type cytokines and the development of "infectious" tolerance in rat cardiac allograft recipients.
Onodera K; Hancock WW; Graser E; Lehmann M; Sayegh MH; Strom TB; Volk HD; Kupiec-Weglinski JW
Harvard Medical School, Department of Surgery, Brigham and Women's Hospital, Boston, MA 02115, USA.
J Immunol (UNITED STATES) Feb 15 1997, 158 (4) p1572-81, ISSN 0022-1767 Journal Code: IFB
Contract/Grant No.: RO1AI23847, AI, NIAID; RO1AI33100, AI, NIAID
Languages: ENGLISH
Document type: JOURNAL ARTICLE

2/3/78 (Item 3 from file: 154)
DIALOG(R)File 154:MEDLINE(R)

08841016 96399103
Induction of Th2 cytokines and control of collagen-induced arthritis by

nondepleting anti-**CD4** Abs.
Chu CQ; Londei M
Kennedy Institute of Rheumatology, London, United Kingdom.
J Immunol (UNITED STATES) Sep 15 1996, 157 (6) p2685-9, ISSN 0022-1767 Journal Code: IFB
Languages: ENGLISH
Document type: JOURNAL ARTICLE

2/3/79 (Item 4 from file: 154)
DIALOG(R)File 154:MEDLINE(R)

08793357 96354996
Induction of "infectious" tolerance to MHC-incompatible cardiac allografts in **CD4** monoclonal **antibody**-treated sensitized rat recipients.
Onodera K; Lehmann M; Akalin E; Volk HD; Sayegh MH; Kupiec-Weglinski JW
Harvard Medical School, Surgical Research Laboratory, Boston, MA 02115, USA.
J Immunol (UNITED STATES) Sep 1 1996, 157 (5) p1944-50, ISSN 0022-1767 Journal Code: IFB
Contract/Grant No.: AI23847, AI, NIAID; AI33100, AI, NIAID
Languages: ENGLISH
Document type: JOURNAL ARTICLE

2/3/80 (Item 5 from file: 154)
DIALOG(R)File 154:MEDLINE(R)

08778938 96396455
Flow-cytometric analysis of peripheral lymphocytes in the rat following penetrating keratoplasty and immunosuppressive treatment.
Klebe S; Coupland SE; Krause L; Hoffmann F
Eye Department, Universitatsklinikum Benjamin Franklin, Berlin, Germany.
Ger J Ophthalmol (GERMANY) May 1996, 5 (3) p137-45, ISSN 0941-2921 Journal Code: BNO
Languages: ENGLISH
Document type: JOURNAL ARTICLE

2/3/81 (Item 6 from file: 154)
DIALOG(R)File 154:MEDLINE(R)

08554040 96161423
Innovative treatment approaches for rheumatoid arthritis. T-cell regulation.
Choy EH; Kingsley GH; Panayi GS
UMDS, Rheumatology Unit, Guy's Hospital, London, UK.
Baillieres Clin Rheumatol (ENGLAND) Nov 1995, 9 (4) p653-71, ISSN 0950-3579 Journal Code: CRY
Languages: ENGLISH
Document type: JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL

2/3/82 (Item 7 from file: 154)
DIALOG(R)File 154:MEDLINE(R)

08431029 96053387
In vivo cytotoxic T-lymphocyte induction may take place via **CD8** T helper lymphocytes.
Lasarte JJ; Sarobe P; Prieto J; Borras-Cuesta F

Universidad de Navarra, Facultad de Medicina, Departamento de Medicina Interna, Pamplona, Spain.
Res Immunol (FRANCE) Jan 1995, 146 (1) p35-44, ISSN 0923-2494
Journal Code: R6E
Languages: ENGLISH
Document type: JOURNAL ARTICLE

2/3/83 (Item 8 from file: 154)
DIALOG(R)File 154:MEDLINE(R)
(c) format only 1997 Knight-Ridder Info. All rts. reserv.

08308590 95329563
Depletion of **CD4**+ and **CD8** + cells eliminates immunologic memory of thyroiditogenicity in murine experimental autoimmune thyroiditis.
Fuller BE; Giraldo AA; Waldmann H; Cobbold SP; Kong YC
Department of Immunology and Microbiology, Wayne State University School of Medicine, Detroit, Michigan 48201, USA.
Autoimmunity (SWITZERLAND) 1994, 19 (3) p161-8, ISSN 0891-6934
Journal Code: A5H
Contract/Grant No.: DK 40721, DK, NIDDK; DK 45960, DK, NIDDK
Languages: ENGLISH
Document type: JOURNAL ARTICLE

2/3/84 (Item 9 from file: 154)
DIALOG(R)File 154:MEDLINE(R)
(c) format only 1997 Knight-Ridder Info. All rts. reserv.

07419561 92368404
The forces driving autoimmune disease.
Roitt IM; Hutchings PR; Dawe KI; Sumar N; Bodman KB; Cooke A
Dept. of Immunology, University College & Middlesex School of Medicine, London, UK.
J Autoimmun (ENGLAND) Apr 1992, 5 Suppl A p11-26, ISSN 0896-8411
Journal Code: ADL
Languages: ENGLISH
Document type: JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL

2/3/85 (Item 10 from file: 154)
DIALOG(R)File 154:MEDLINE(R)
(c) format only 1997 Knight-Ridder Info. All rts. reserv.

06620943 91370929
Reprogramming the immune system for tolerance with monoclonal **antibodies**.
Cobbold SP; Qin SX; Waldmann H
Department of Pathology, Cambridge University, UK.
Semin Immunol (UNITED STATES) Nov 1990, 2 (6) p377-87, ISSN 1044-5323
Journal Code: A61
Languages: ENGLISH
Document type: JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL

2/3/86 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 1997 American Chemical Society. All rts. reserv.

126058863 CA: 126(5)58863v PATENT
Induction of immunological tolerance by the use of non-depleting anti-CD4 antibodies
INVENTOR(AUTHOR): Knowles, Robert W.; Cavender, Druie E.; Thomas, Judith M.
LOCATION: USA

ASSIGNEE: Johnson and Johnson Corporation
PATENT: PCT International ; WO 9636359 A1 DATE: 19961121
APPLICATION: WO 96US6912 (19960516) *US 443739 (19950518)
PAGES: 20 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-039/395A; C07K-016/28 DESIGNATED COUNTRIES: AL; AM; AT; AU; AZ; BB; BG; BR; BY; CA; CH; CN; CZ; DE; DK; EE; ES; FI; GB; GE; HU; IS; JP; KE; KG; KP; KR; KZ; LK; LR; LS; LT; LU; LV; MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI DESIGNATED REGIONAL: KE; LS; MW; SD; SZ; UG; AT; BE; CH; DE; DK; ES ; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; ML

2/3/87 (Item 2 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 1997 American Chemical Society. All rts. reserv.

117169437 CA: 117(17)169437t PATENT
Nondepleting CD4-specific monoclonal antibodies for the treatment of insulin-dependent diabetes mellitus (IDDM)
INVENTOR(AUTHOR): Cooke, Anne; Waldmann, Herman
LOCATION: UK,
ASSIGNEE: University College London
PATENT: PCT International ; WO 9211869 A1 DATE: 920723
APPLICATION: WO 92GB74 (920114) *GB 91741 (910114)
PAGES: 19 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-039/395A
DESIGNATED COUNTRIES: AT; AU; BB; BG; BR; CA; CH; DE; DK; ES; FI; GB; HU; JP; KP; KR; LK; LU; MG; MW; NL; NO; PL; RO; RU; SD; SE; US
DESIGNATED REGIONAL: AT; BE; BF; BJ; CF; CG; CH; CI; CM; DE; DK; ES; FR; GA; GB; GN; GR; IT; LU; MC; ML; MR; NL; SE; SN; TD; TG

2/3/88 (Item 1 from file: 351)
DIALOG(R)File 351:DERWENT WPI
(c)1997 Derwent Info Ltd. All rts. reserv.

011033929
WPI Acc No: 97-011853/199701
XRAM Acc No: C97-003237
Amt. of **non-depleting** anti-**CD4 antibody** effective to induce immunological tolerance - useful to inhibit allo-graft rejection in primate subject, specifically bone marrow allo-graft
Patent Assignee: JOHNSON & JOHNSON CORP (JOHJ)
Inventor: CAVENDER D E; KNOWLES R W; THOMAS J M
Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Main IPC	Week
WO 9636359	A1	19961121	WO 96US6912	A	19960516	A61K-039/395	199701 B
AU 9657479	A	19961129	AU 9657479	A	19960516	A61K-039/395	199712

Priority Applications (No Type Date): US 95443739 A 19950518
Filing Details:

Patent	Kind	Filing Notes	Application	Patent
WO 9636359	A1			

Designated States (National): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN
Designated States (Regional): AT BE CH DE DK EA ES FI FR GB GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG

AU 9657479	A	Based on	WO 9636359

Language, Pages: WO 9636359 (E, 17)

2/3/89 (Item 2 from file: 351)
DIALOG(R)File 351:DERWENT WPI
(c)1997 Derwent Info Ltd. All rts. reserv.

009140953
WPI Acc No: 92-268391/199232
XRAM Acc No: C92-119699
Use of single **non-depleting CD4** monoclonal **antibody** - for treatment of insulin-dependent diabetes mellitus (IDDM), arrests loss of insulin producing cells
Patent Assignee: UNIV COLLEGE LONDON (UNLO)
Inventor: COOKE A; WALDMANN H
Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Main IPC	Week
WO 9211869	A1	19920723	WO 92GB74	A	19920114	A61K-039/395	199232 B
AU 9211647	A	19920817	AU 9211647	A	19920114	A61K-039/395	199245
			WO 92GB74	A	19920114		
EP 567490	A1	19931103	EP 92902288	A	19920114	A61K-039/395	199344
			WO 92GB74	A	19920114		
JP 6504283	W	19940519	JP 92502777	A	19920114	A61K-039/395	199424
			WO 92GB74	A	19920114		
AU 668081	B	19960426	AU 9211647	A	19920114	A61K-039/395	199624

Priority Applications (No Type Date): GB 91741 A 19910114
Filing Details:

Patent	Kind	Filing Notes	Application	Patent
WO 9211869	A1			
		Designated States (National): AT AU BB BG BR CA CH DE DK ES FI GB HU JP KP KR LK LU MG MW NL NO PL RO RU SD SE US		
		Designated States (Regional): AT BE CH DE DK ES FR GB GR IT LU MC NL OA SE		
AU 9211647	A	Based on		WO 9211869
EP 567490	A1	Based on		WO 9211869
		Designated States (Regional): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE		
JP 6504283	W	Based on		WO 9211869
AU 668081	B	Previous Publ.		AU 9211647
		Based on		WO 9211869

Language, Pages: WO 9211869 (E, 19); EP 567490 (E); JP 6504283 (5)

2/3/90 (Item 3 from file: 351)
DIALOG(R)File 351:DERWENT WPI

008503137
WPI Acc No: 91-007221/199101
XRAM Acc No: C91-003203
Non-depleting CD4 and **CD8** monoclonal **antibodies** - for inducting tolerance to foreign antigens in transplant rejection, auto-immune disease, etc
Patent Assignee: COBBOLD S P (COBB-I); WALDMANN H (WALD-I); WELLCOME FOUND LTD (WELL)
Inventor: COBBOLD S P; WALDMANN H
Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Main IPC	Week
WO 9015152	A	19901213				B	199101 B
PT 94214	A	19910208				B	199109
AU 9057258	A	19910107				B	199115
EP 474691	A	19920318	EP 90908270	A	19900531	B	199212
ZA 9004174	A	19920226	ZA 904174	A	19900530	B	199213
DD 296843	A5	19911219	DD 341218	A	19900531	B	199221
JP 4505919	W	19921015	JP 90508030	A	19900531	B	199248
			WO 90GB840	A	19900531		
HU 61341	T	19921230	HU 905134	A	19900531	B	199306
			WO 90GB840	A	19900531		
AU 657255	B	19950309	AU 9057258	A	19900531	B	199520
EP 474691	B1	19961113	EP 90908270	A	19900531	B	199650
			WO 90GB840	A	19900531		

DE 69029134	E	19961219	DE 629134	A	19900531	B		199705
			EP 90908270	A	19900531			
			WO 90GB840	A	19900531			
ES 2096588	T3	19970316	EP 90908270	A	19900531	B		199718
NZ 233889	A	19970624	NZ 233889	A	19900531	B		199732

Priority Applications (No Type Date): GB 8912497 A 19890531
Filing Details:

Patent	Kind	Filing Notes	Application	Patent
WO 9015152	A			
		Designated States (National): AU CA FI HU JP KR US		
		Designated States (Regional): AT BE CH DE DK ES FR GB IT LU NL SE		
EP 474691	A			
		Designated States (Regional): AT BE CH DE DK ES FR GB IT LI LU NL SE		
JP 4505919	W	Based on	WO 9015152	
HU 61341	T	Based on	WO 9015152	
AU 657255	B	Previous Publ.	AU 9057258	
		Based on	WO 9015152	
EP 474691	B1	Based on	WO 9015152	
		Designated States (Regional): AT BE CH DE DK ES FR GB IT LI LU NL SE		
DE 69029134	E	Based on	EP 474691	
		Based on	WO 9015152	
ES 2096588	T3	Based on	EP 474691	

Language, Pages: EP 474691 (44); ZA 9004174 (57); JP 4505919 (19); EP